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INTRODUCTION 
 
                        Indian subcontinent is famous for its own medical system, which 
strictly precincts with principles of nature called INDIGENOUS system. This includes 
Siddha, Ayurveda, and Unani. 
                        The Siddha system of medicine, “THE GIFT OF NATURE”, which 
was originated from Lord Shiva and was gifted to Tamilians by people called 
Siddhars. Siddhars are people who are not only physicians, they are social reformers. 
                        Siddha science considers nature and human as essential. Man is a part 
and parcel of the universal nature. Nature functions well in human system. A man who 
identifies himself with nature is sure to know everything of nature as well. Saint 
THIRUVALLUVAR in his eternal Tamil classic THIRUKKURAL. 
                           “Í¨Å ´Ç¢ °Úµ¨º ¿¡üÈõ ±ýÈ ³ó¾¢ý 
                     Å¨¸¦¾¡¢Å¡ý ¸ð§¼ ¯ÄÌ.” 
                                                              -¾¢ÕìÌÈû -27 
   
         Says that those who have understood the five senses of taste, sight, the nature of 
the world. This holds well in the case of a good physician too. Ignoring of nature’s 
law upsets the human system and diseases occur. 
  
                    According to siddhars the human body is composed of ninety-six 
thathuvas or constituents principles in nature including elements, bodily and mental 
organs, e.t.c. and further add that the human  body is consist of 72,000 blood vessels, 
13,000 nerves, 10 main arteries, 10 vital airs (prana) all together in the form of a 
network, and it is owing to the derangement of the three humours becomes liable to 
4448 diseases. This is well explained in the following verses from ISWARA’S 
MEIGNANA NAADI 
 
          “ãÄ¦ÁØÀò¾£Ã¡Â¢ÃÁ¡õ ¿¡Ê 
      Ó¨Éò ¦¾ØóÐ Å¨Ä§À¡Ä ÓÊó¾§¾¡§¼ 
  §¸¡ÄÁ¡öô À¾¢ýãÅ¡Â¢Ãõ ¿ÃõÒ 
  §¸¡÷¨ÅÂ¡ö Ýúó¾¢ÕìÌõ ÜðÊüÌû§Ç 
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  ¸¡ÄÁ¡õ ¿¡ÊÀòÐ Å¡ÔÀòÐ 
  ¸¾¢ò¾¦¾øÄ¡ Óì§¸¡÷¨Åô À¨¸Â¢É¡§Ä 
  ¿¡ÄÉ¡Ä¡Â¢ÃòÐ ¿¡Ûü§È¡Î 
  ¿Å¢ø ¿¡üÀò ¦¾¡ñ§½Â¡ö ¿¡ð¼Ä¡§Á.” 
 
-®ŠÅÃ ¦Áö»¡É ¿¡Ê 
 
 
              Humoral pathology explains that all disease are caused by the mixture of the 
three cardinal humours viz VATHAM, PITHAM, IYYAM. Those three humours and 
the relative proportions are responsible for a person’s physical and mental qualities 
and dispositions. 
 
 The external air corresponds to the internal VATHAM 
 
  The external heat corresponds to the internal  PITHAM 
 
 The external water corresponds to the internal IYYAM. 
 
                Human body is thus linked with the external world.  The three humours 
maintain the upkeep of the human body through their combination. An alteration of 
these three humours causes diseases. 
 
                         VATHA is a prime  humour . The common symptom of altered 
vatham is pain and it is the accepted as a derangement of vatham ,  the first cause for 
occurrence of diseases. 
                    
                            Pain is a helpful sign diagnosing a problem. Without pain, one might 
seriously hurt themself without knowing it, or might not realize  medical problem that 
needs treatment. Once treated the problem, pain usually goes away. However, 
sometimes pain goes on for weeks, months or even years is named  chronic pain.The 
above told symptoms are explained in siddha texts under the title of kumbavatham in 
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yugi vaithiya chindhamani 800.So finaly the disease (“periarthritic shoulder” or 
“frozen shoulder”) is compared with “KUMBAVATHAM” here. 
 
                             Frozen shoulder is a common disorder which is characterised by 
pain and loss of movement .  Its cause is poorly understood and its management is 
disputed because of lackof supporting evidence. The great pathologist Duplay, in 
1872, used the term “peri-arthritis scapulohumerale” to describe the condition. In 
1934, Codman introduced the term “frozen shoulder”. 
                             
                       The prevalence to be slightly greater than 2% in the general population. 
It is more common in women and between the ages of 40 and 60 years. Recurrence is 
unusual and both shoulders are affected in between 6% and 34% of cases. 
 
                “KANTHAGA PARPAM” is the one of the medicine quoted in siddha 
literatures for treating kumbavatham. So I pledge here to take my dissertation to put 
my whole effort to make a very best treatment for kumbavatham with kanthaga 
parpam.  
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AIM AND OBJECTIVES 
AIM OF THE STUDY:  
Primary aim: 
            To assess the  safety and efficacy of the siddha  drug, kanthaga parpam. 
Secondary aim: 
             To evaluate the effect of kanthaga parpam to reduce the pain in the shoulder 
joints,   radiating pain, tenderness, stiffness and difficulty to move the joints. 
OBJECTIVES OF THE STUDY: 
 To collect the authorised measures and review the ideas of kumbavatham in 
Siddha and modern literatures. 
 To have an idea about the relation of the disease with age, 
occupation,economic status, habits, family history and climatic conditions. 
 To expose the efficacy of siddhars diagnostic principles such as mukkutram, 
envagai thervugal, ezhu udalthadhukkal, neerkuri and neikuri. 
 To have detailed clinical investigations. 
 To have a clinical trial on the disease “kumbavatham” with the siddha 
medicine, “kanthaga parpam” . 
 To evaluate , 
 Chemical [qualitative & quantitative] 
 Toxicological [acute & subacute] 
 Pharmacological action 
 To handle the modern parameters to confirm the diagnosis and prognosis of the 
study. 
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REVIEW OF LITERATURES 
SIDDHA ASPECTS 
 
“thÍé‹  Fz¤Jl‹  NlQjš 
 thÍéå  l§fëš nehŒfS©L 
  thÍéš Fë®¢Ájh‹  Toonth 
 thÍéš mdšjU« beŒ¥gikªjhš 
thÍÎ« ml§»L« thŒikæJ 
 thÍé‹ Ãâfis¥ ngh¡»lnt 
tF¤ÂL« Kåbkhê f©oLnk” 
- Á¤j kU¤Jth§f RU¡f« 
In our ancient Siddha literature the diseases are classified into 4448 types based 
on the mukkutra theory (Vali (tsp), Azhal, Iyam). However Vali(tsp) diseases got a 
major role among them, here are so many types of vali (tsp) diseases and 
kumbavatham is one variety which is taken for my dissertation.  
As per our Siddha aspect the first phase in human life is attributed to vali 
(tsp), the middle to Azhal and the last phase to Iyam. This is known from the 
following verses. 
 
 ‘thjkha; gilj;J gpj;j td;dpakha; fhj;J 
 rpNyj;Jk rPjkha; Jilj;J 
      - Njiuah; kUj;Jt ghujk; 
The details of Vali (tsp) have been dealt before reviewing the specific signs 
and symptoms of kumbavatham. 
 
17 
 
 
DEFINITION 
 Vali (tsp) is one of the three humours. Among the five elements (pancha 
boothas) Vali (tsp) is formed by Vali (Air) and Vin (sky). In a healthy individual the 
existence of the three humours are in the ratio of 1: 1/2 :1/4 respectively. When the 
three humours are in the above said ratio, they are called as thathus and when they are 
dearranged, they are called as kutram. 
 
 The alteration of the above ratio may be due to environmental factors, diet and 
behaviors etc. When Vali (tsp) is affected the other two thathus are also affected that 
leads to the pathological changes. This is known from the following quotation. 
  
 ‘thjkyhJ Nkdp nflhJ”   
       - Njiuah; 
Seats of Vali (tsp) 
 ‘ehnkd;w thjj;Jf; fpUg;gplNk Nfsha; 
 ehbf;Ff; fPnod;W etpyyhFk;” 
       - A+fpKdp 
Vali (tsp) Generally lives in: 
• Abanan 
• Edakalai 
• Kaamakodi 
• Undhiyin Keezh Moolam 
• Hip region 
• Bones 
• Muscles 
• Nerves 
• Joints 
• Skin 
• Hair follicles 
• Stools 
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Natural Properties of Vali (tsp) 
• Giving Briskness 
• Respiration 
• Functioning the mind, thoughts and body. 
• Regulation of fourteen physiological reflexes (Vegams) 
• Uniform functioning of the seven udal kattugal. 
• Strengthening the five sensory organs. 
 
 
CHARACTERISTICS OF VALI (tsp) 
• Body Pain 
• Pricking Pain 
• Tearing Pain 
• Nerve Weakness 
• Shivering 
• Mental distress 
• Dryness 
• Movements 
• Joint Pain 
• Traumatic Pain 
• Dislocation of the joints of upper and lower limbs 
• Piloerection 
• Poldypsia 
• Severe pain in the calf and thigh muscles 
• Bony pricking pain 
• Anuria 
• Constipation 
• Difficulty in flexion and extension of the limbs 
• All tastes like astringent 
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• Astringent salivation 
• Darkness of Skin, stools and urine 
 
 
Relation with five elements: 
Vali (tsp)  -  Vali (Air) & Vin 
 Azal   -  Thee 
 Iyam   -  Neer & Mann 
 
 Vali (tsp) has “Vali (Air)” and “Vin” as it’s elemental constituents. If “Vali ” 
and “Vin” or any one of them is decreased (or) increased from the normal level, it will 
surely lead to pathological state of Vali (tsp). 
 
 Regarding diet, bitter Pungent and astringent tastes contains “Vali (Air)” and 
bitter alone contains “Vin”. So if these are consumed in improper amounts results in 
the vitiation of vali (tsp) and eventually vali (tsp) diseases. The six tastes and their 
constituents elements are as follows. 
Sweet   -  Mann + Neer  
Sour   -  Mann + Thee 
Bitter   -  Neer + Thee 
Bitter   -  Vali (Air) + Vin 
Pungent  -  Vali (Air) + Thee 
Astringent  -  Mann + Vali (Air) 
Relation with Tastes 
 ‘Gsp Jth; tpQ;Rq; fwpahw; G+hpf;Fk; thjk; 
 xsp Ath; ifg;Ngwpy; gpj;jQ; rPWk; - fpspnkhopNa 
 fhh;g;gpdpg;G tpQ;rpw; fgk; tpQ;RQ; rl;b ujr; 
 Nrug; Gzh; NehaZfhNj.” 
       - fz;Zrhkpak; 
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Source and astringent are the tastes that increase Vali (tsp) 
‘thj Nkypl;lhy; kJuk; GspAg;G 
 NrjKwr; nra;Ak; rPiwak; - Xjf;Nfs; 
 fhue; Jth; frg;G fhl;LQ; Ritnay;yhk; 
 rhug; ghpfhuk; rhw;W” 
       - fz;Zrhkpak; 
 
 
Varieties of Vali (tsp): 
 The Vali (tsp) is dived into 10 types according to their location and functions 
described in the siddha texts. They are 
Uyirkkaal (Piranan) 
Kezhnokkum Kaal (Abanan) 
Paravukaal (Viyanan) 
Mel Nokkumkaal (Udhanan) 
Nadukaal (Samanan) 
Naagan 
Koorman 
Kirugaran 
Devadhathan 
Thananjeyan. 
 
 
 
Aetiology of Vali (tsp) Diseases 
 The common etiological factor for all types of Vali (tsp) diseases including 
kumbavatham” have been described generally in Yugi Vaidhya Chindhamani – 800; 
Agasthiyar Kanma Kaandam – 300 and Agasthiyar Guna Vagadam. 
 
Agasthiar Gunavangadam 
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‘njhy;iy nra;a ,d;Wk; ntF thj Neha;fs; 
njhy;Yyfpy; khe;jpUf;Fr; fhz;gJz;L 
vy;iyapy;iy thjNeha; Neh;ik jd;ik 
,ay;ghf mwpe;jplNt tpguq;NfNs” 
 
‘tpguklh mrjp rd;dp %is NehT 
tphpthd %isaJ kpUJthfp 
mtdpjdpy; %j;jpuf; Fz;bf;fha; tpahjpahYk; 
jtKdpth; jPh;fhf;if NkfNuhfk; 
jd;ikAs;s Kj;jz;Lf; nfhb tpahjp 
mtkpyhg; ghpr euk;gOj;jq; fz;lha; 
mZFklh thjNeha; MFk; ghNu.” 
 
‘mZFklh khkprj;jpd; tpahjpahYk; 
mg;gNd R+jfj;jpd; ngUf;fhYk; 
Fzkpy;yh ,urk; tq;fk; jpd;dyhYk; 
FbnfLj;j thjkJ cz;ghkg;gh.” 
      - mfj;jpah; Fzthflk; 
• Brain diseases 
• Rental Discuses 
• Sexually transmitted diseases 
• Diseases of the vertebral column & spinal cord 
• Mennorhagia 
• Take in property prepared medicine of mercury and will lead will cause vatha 
diseases. 
 
In Agasthiyar Kanma Kaandam – 300 
‘E}nyd;w thjk; te;j tif jhNdJ 
Jz;ikaha;f; fd;kj;jpd; tifiaf; NfS 
fhypNy Njhd;wpaJ fLg;gNjJ 
iffhypy; Klf;fpaJ tPf;fNkJ 
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NfhypNy gLfpd;w tpUl;rkhd 
Foe;ij kue;jd;id ntl;ly; Nky; Njhy; rPty; 
ehypNy rPt nra;J fhy; Kwpj;jy; 
ey;y gz;G jio Kwpj;jy; eypj;jy; jhNd 
         - ghly; 56 
• Cutting the trees. 
• Breaking the legs of living animals 
• Cutting the branches and leaves of living trees. 
 
In Yugi Vaidhya Chindhamani – 800 
‘vd;dNt thje;jh ndz;gjhFk; 
,fj;jpNy kdpjh;fSk; nra;AkhW 
gpd;dNt nghd;djidNa NrhuQ; nra;J 
nghpNahh;fs; gpuhkziuj; J}ldpj;Jk; 
td;d Njt nrhj;jpy; NrhuQ; nra;Jk; 
khjh gpjh FUit kwe;j Ngh;f;FK 
fd;dNt epe;ij nra;jhy; 
fhaj;jpw; fhye;jpLNk thje;jhNs” 
        - ghly; 243 
 
‘jhndd;w frg;NghL Jth; Giwg;G 
rhjfkha; kpQ;RfpYk; rikj;j td;dk; 
Mndd;w thwpdJ Grpj;jyhYk; 
Mfhaj; NjwyJ Fbj;jyhYk; 
ghndd;w gfYwf;f kpuh tpopg;G 
gl;bdpNa kpfTWjy; ghunka;jy; 
Njndd;w nkhopahh; Nkw;rpe;ijahjy; 
rPf;fpukha; thjkJ nrdpf;Fe;jhNd.” 
        - ghly; 244 
 
‘Mdd tud;widNa kjpah khe;jh; 
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mfjp guNjrpah; fl; fd;d kPahh; 
Nfhdhd FUnkhopia kwe;j Ngh;fs; 
nfhiy fsT ngha;fhkq; Fwpj;j Ngh;f;F 
Cid rle;jd;dpy; thjk; te;J  
cw;gtpf;Fk; Ntjj;jpd; cz;ikjhNd 
        - ghly; 253 
 
‘gfuNt thjkJ Nfhbj; jg;Ngh 
 gz;ghf ngz;Nghf kJjhd; nra;apy; 
 efuNt ntFJ}u top elf;fpy; 
 xspuhd fhw;WNk gdp Nkw;gl;lhy; 
 kpfuNt fha;fs; fdp fpoq;F jd;id 
 kpf tUe;jp kPwpNa japh;jhd; nfhz;lhy; 
 KfuNt KJnfYk;ig KWf;fp nehe;J 
 Koq;fhYk; fizf;fhYk; fLg;G cz;lhf;Fk;” 
        - ghly; 285 
 
 
• Breach of trust 
• Abusing the elderly people and priests 
• Exploitation of charitable properties 
• Ingratitude with mother, father and teacher 
• Excessive consumption of bitter, astringent and pungent taste foods. 
• Intake of spoiled rice 
• Drinking of rain water 
• Sleeping during day and awakening during night  
• Undue starvation 
• Lifting or carrying of heavy loads 
• Excessive lust 
• Disrespectful attitude with God 
• Refusing food for destitute and her mites 
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• Disregarding the advice of preceptors 
• Involving in murdering stealing, lieing and lustful activities 
• Indulging in sexual act during exaggerated vali (tsp) 
• Walking for a klong distance 
• Exposure to chillness 
• Excessive intake of curd immediately after excessive intake of vegetables, 
fruits will lead to twisting pain in the vertebral column and pain in the ankle 
and knee joints. 
 
Classification of Vali (tsp) diseases:  
 Various Siddha texts gives different classification of Vali (tsp) diseases as 
follows: 
Sl. No Name of the Siddha Text Types 
1. 
Agathiyar 2000 
vz;gJ thjkhF kpUtifg;gLj;jpf; fhzpd; 
ez;GW miuf;F NkNy ehw;gJ thjkhFk; 
gz Nruiuf;Ff; fPNo gj;J ehd;fhFnkd;W 
cz;L Nrh; FoypdhNs thjj;jpd; $WjhNd 
80 
2. Agathyar Gurunadi – 235 84 
3. 
Agasthiyar Rathina Surikkaam – 500  
‘kw;wNk thjNuhfk; tif vz;gj;J ehNy” 
84 
4.  Astaanga Sangiragam 85 
5. 
Bohar Vaidhiyam – 700 
‘thr;nrd;w thjk; vz;gJTk; NghFk;” 
80 
6. Jeeva Rakshaamiradham 80 
7. Noi Naadal and Noi Mudhal Naadai – Part II 85 
8. Thanvanthiri Vaidhiyam 80 
9. Theraiyar Vaidhiyam 81 
10. 
Yugi Vaidhya Chindhaamani perunool – 800  
vd;dNt thjkJ vz;gjhFk;. 
80 
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Clinical Features: 
 The signs and symptoms of Vali (tsp) diseases have been given in many 
Siddha classical text books as follows: 
 
In Agasthiyar – 2000 
 ‘thjj;jpd; FzNknjd;dpy; kaf;Fe;jpnaq;Fk; kyh; rptpf;Fk; 
 ghjq; Fsph;e;J rUthq;fk; gw;wp elf;F Kfq;fLFQ; 
 rPj;JlNd tapW Gz;zhQ; rphpg;gpj; jJe;njwp %r;rhk; 
 Nghjj; jz;zPh;jhd; thq;Fk; GfOk; gQ;r FzkhNk”. 
         - mfj;jpah; 
• Giddiness 
• Stabbing pain in the face 
• Redness of eyes 
• Peptic ulcer 
• Abdominal distension 
• Joint pain in upper and lower limbs Numbness in the limbs 
• Oliguria 
• Drowsiness and 
• Chillness of body 
 
Agasthiyar Naadi: 
  ‘nrhy;yNt thjkJ kPwpw;why; 
   Nrhh;tile;j thAtpdhy; Njfnkq;Fk; 
   nky;y iffhy; mrjpAz;lhFk; 
   nka; Klq;Fk; epkpunthz;zhj jpkph; cz;lhFk;” 
- mfj;jpah; ehb 
• Weakness of the limbs 
• Stuggishness 
• Stiffness and 
• Numbness 
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Theraiyar Vaagadam: 
‘thj tPW md;dkpwq;fhJ fLg;Gz;lhk; tz;zKz;lhk; 
NkhJ fl;L Nuhfk; fuKz;lh kpUfYkh Kwq;fhnjd;Wk; 
XJ R+hpa thj kdyhF eLf;fKz;lhk; nghUs;fsha;e; 
jPnjdNt euk;gprpj;J re;Jfs; NjhWk; ,Lq;Fe;jhNs” 
- Njiuah; thflk; 
 
• Loss of appetite 
• Back ache 
• Fever 
• Cough 
• Sleeplessness 
• Shivering and 
• Pain in joints. 
 
 
 
‘jf;f thA Nfhgpj;jhy; re;JTise;J jiy Nehth 
kpf;f %hp nfhl;lhtp tpl;lq;nfhpA kyq;fl;Lk; 
xf;f euk;Gjhd; KldqFKyh;e;J tha; eP&wp tUk; 
kpf;f FspUk; eLf;fKkha; Nkdp Fswp tUq;fhNz” 
- ghly; 42. 
 
• Pain in the joints 
• Head ache 
• Excessive yawning 
• Constipation 
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KUMBAVATHAM 
Definition  
                Kumbavatham is one of the vali ( ÅÇ¢  ) disease described in   ``Yuki  
vaidhta  chindhamani -800 ``. It is a condition dealing with the involvement of the 
shoulder joints , acute pain in shoulder joints , tenderness, stiffness, difficulty in 
moving the shoulder joints ,diffuse pain in the shoulder with radiation down to the 
middle of the upper arm . 
Aetiology  
        The aetiolgical factors of vali ( ÅÇ¢ ) disorder were described in 
various siddha texts. The causes are also applicable to kumbavatham. 
Hence they are briefly mentioned below.  
         In yugi vaidhya chindhaamani, the following causes are given as 
follows.  
 ¿Å¢Ä§Å §¾¡ñÁ£Ðõ ¸Ã¾¢ý Á£Ð 
       ¿Ä¢óÐ ¦Áò¾ Å¡¸¢§Â ¿º×ñ¼¡Ìõ 
 ¸Å¢Ä§Å ¸ýÉ¦Á¡Î ¿Â¡Éóò ¾¡Ûíì 
       ¸ÎòÐ§Á Å¢ÕÅ¢ÕôÒ ¦Á¡¢×íì ¸¡Ïõ  
ÐÅ¢Ä§Å ÐÊôÀ¡Ìõ º¢ÃÍ ¾ýÉ¢ü 
 ÍÆüÈ¢§Â ¿¡À¢ì¸£ú ÅÄ¢Ô Óñ¼¡Ìõ 
 «Å¢Ä§Å ÂÊ¿¡ì¸¢ ÄÆýÚ ¸¡Û 
         ÁÄÕ§Á ÅÕõ§À Å¡¾óò ¾¡§É      
              -ä¸¢ ¨Åò¾¢Â º¢ó¾¡Á½¢ 800  
• Burning pain in shoulder joints and upper limbs  
• Burning sensation in the jaws and eyes  
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• Twitching over the scalp 
• Guiddiness and fever  
• Pain in the lower abdomen  
• Glossitis  
 
According to the physiological function, vali is ten types. They are  
 
S.NO VATHAM GENERAL FEATURES 
CHANGES       IN 
KUMBAVATHAM 
1. Piranan(Uyir Kaal)  
Responsible for respiration 
and it is necessary for proper 
digestion  
 
Normal 
2. Abanan(Kizhnokkumkaal) 
Responsible for  all 
downward forces such as 
voiding of urine, stools, 
semen, menstrual flow  
Normal 
3. Viyanan(paravukaal) 
Dwells in the skin and is 
concerned with the sense of 
touch... extension and 
flexion of the parts of the 
body and distribution, of the 
nutrients to various parts of 
the body 
 
 
 
 
Affected 
5. Samanan(nadukkaal) 
Considered essential for 
proper digestion, 
Normal 
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assimilation and carries the 
digested nutrients to each 
and every organ 
 
6. Nagan  
Helps in opening &closing 
of eyelids 
 
 
Normal 
7. Koorman  
Responsible for vision, 
lacrimation  and yawning 
 
Normal 
8. Kirugaran 
Induces  appetite, salivation, 
all secretions in the body 
including nasal secretion and 
sneezing 
 
Normal 
9. Thevathathan  
Induces and stimulates a 
person to become alert, get 
anger, to quarrel, to sleep etc 
 
Normal  
10. Dhananjeyan  
Resides in the cranium and 
produces bloating of the 
body after death. This leaves 
from the body after 3days of 
death, forming a way 
through the skull. 
---- 
 
In Kumbavatham,  Viyanan will be mainly affected  . 
 
 
 
FUNTIONS OF AZHAL: 
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 ‘grpjhfk; Xq;nfhspfz; ghu;itgz; lj;J 
 Urpnjup rj;jp ntk;ik tPuk; - crpj 
 kjp$u;j;j Gj;jptdg; gspj;Jf; fhf;Fk; 
 mjpfhup ahq;fh doy;” 
  kUj;Jt jdpg;ghly; gf;fk;16 
 
Azhal is functionally divided in to five types. They are 
 
S.NO PITHAM 
NORMAL 
FEATURES 
CHANGES IN 
KUMBAVATHAM 
1. Anarpitham(Akkuanal) 
Peps up the appetite and 
aids in digestion. 
Normal 
2. Ranjagapitham(Vanna eri) 
Responsible for the color 
and contents of blood. 
Normal 
3. Sathagapitham(Attralangi) 
Controls the whole body 
and is held responsible 
for fulfilling a purpose. 
Affected 
4. Pirasagapitham(Ollolithee)  
Dwells in the skin and 
concerned with the shine, 
glow, texture and its 
complexion 
Normal 
5. 
Alosagapitham(Nokku 
Azhal) 
Responsible for the 
perception of vision. 
Normal 
 
FUNTIONS OF IYAM: 
‘jplkPA nkd;gpizg;Gj; jpz;ikAw;w ahg;Gk; 
mlNyu; tOtOg;Gk; Mf;iff; - fplu;f;F 
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ntUthg; nghWikAk; Nkyhd fhg;ghk; 
ngUikj;jh ikankdg; NgR” 
kUj;Jt jdpg;ghly; gf;fk;20 
It is of five types. They are 
 
In Kumbavatham, santhigam  affected.     
S.NO KABHAM GENERAL FEATURES 
CHANGES IN 
KUMBAVATHAM 
1. 
Avalambagam(Alli 
Iyyam)  
Lies in the respiratory organs, 
exercises authority over other 
khapas and controls the heart and 
circulatory system. 
Normal 
2. 
Kilethagam(Neerpi 
Iyyam)  
Found in stomach as its seat, 
moistens the food, softens and 
helps to be digested. 
Normal 
3. 
Pothagam(Suvaikanna 
Iyyam)  
Hold responsible for the sensory 
perception of taste. 
Normal  
4. 
 
 
Tharpagam(Niraivu 
Iyyam)  
Presents in the head and is 
responsible for the coolness of the 
eyes, sometimes may be referred to 
as cerebrospinal fluid 
Normal 
5. 
Santhigam(Ondri 
Iyyam)  
Necessary for the lubrication and 
the free movements of joints. 
Affected 
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UDAL KOORUGAL (SEVEN PHYSICAL CONSTITUENTS): 
‘,ukpuj; je;jir nea; epznkd;G kr;irtPe;njd;NwOk; KiwNa” 
 rujnkhL nka;kdj;J epiwTjUk;capUl;Lj;jhq;fp apUf;Fk; 
 cuKjTk; NkLgs;sk; epuTk; nea;g; gira+l;Lk; Xq;fp epWj;Jk;  
 gue;njd;gpd; JisfnlhWk; epuk;gpLq;fs; KisNjhd;wg; gz;Zk; njuptha;” 
       -rpj;j kUj;J}thq;fr; RUf;fk; -gf;fk;334 
The human body is made of seven basic physical constituents. These 
constituents should be in harmony and function normally. Any variation in them will 
lead to their functional deviations. 
The Natural characters of the seven physical constituents  
S.NO UDAL KATTUGAL GENERAL FEATURES 
CHANGES IN 
KUMBAVATHAM 
1. 
Saaram 
 (digestive essence) 
Responsible for the 
growth& development. It 
keeps the individual in good 
temperament and it enriches 
the bood. 
Normal  
2. Senneer (blood) 
Responsible for the colour 
of blood and for the 
intellect, nourishment, 
strength, vigour and valour 
of the body.  
Normal 
3. Oon (muscle) 
Gives lookable contour to 
the body as needed for the 
physical activity. It feed the 
fat next day and gives a sort 
of plumpness to the body  
Affected 
4. Kozhuppu (fat) 
Lubricates the organs to 
facilitate frictionless 
Normal 
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functions. 
5. Enbu (bones) 
Supports & protects the 
vital organs, gives the 
definite structure of the 
body and responsible for the 
posture and movements of 
the body 
Affected 
6. Moolai (bone marrow) 
Nourishes the bone marrow 
and brain which is the 
centre that controls other 
systems of body 
Normal 
7. 
Sukkilam/ 
Suronitham(sperm/ ova) 
Responsible for 
reproduction 
 
 
THE VARIATIONS OF THE PHYSICAL CONSTITUENTS: 
1. SAARAM  
           Increased Saaram:Leads to diseases of increased kapham like indigestion Etc 
            Decreased Saaram : Leads to loss of weight, tiredness, lassitude, dryness of the 
skin and diminished activity of the sense organs. 
2. SENNER 
 Increased Senner : Causes boils in different parts of the body throbbing pain, 
anorexia, mental disorder, splenomegaly, Colicky pain., increased blood pressure, 
reddish eye and   Skin, jaundice, haematuria etc. 
 Decreased Senner : Leads to anaemia, tiredness, neuritis and lassitude, Pallor of 
body. 
3. OON  
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 Increased Oon : Oon in excess causes cervical lymph adenitis, venereal ulcer, 
tumour in face, abdomen, thigh genitalia etc are the signs of increased Oon 
 Decreased Oon : Leads to impairment of sense organs, joints jaw, thigh and 
genitalia gets shortened 
4. KOZHUPPU 
 Increased Kozhuppu: Identical to that of increased Oon associated with 
Dyspnoea and loss of acidity     
Decreased Kozhuppu: Leads to pain in the hip region and diseases of the spleen 
5. ENBU 
 Excess Enbu : Growth in bones and teeth 
 Decreased Enbu : Loosening of teeth and nails and Splitting and falling of hair 
6. MOOLAI 
 Increased Moolai : Causes heaviness, swollen eyes, swollen phalanges, 
Oliguria and non healing ulcers 
 Decreased Moolai : Causes osteoporosis and sunken eyes 
7. SUKKILAM / SURONITHAM 
 Excess Sukkilam/Suronitham : Causes lust towards women and cause Urinary 
calculus 
 Decreased Sukkilam/Suronitham : Causes failure in reproduction, pain in the 
genitalia. 
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KAALA MARUBADUGAL: 
PARUVAKALAM (SEASONS): 
              According to ancient tamilians, the one year is divided in to six seasons and 
each season consists of two months and the year starts from Margazhi. 
 
S.NO KAALAM TAMIL MONTHS 
MUKKUTTRA   
MARUPAADUGAL 
1. Kaar Kaalam 
Aavani & Purattasi 
Aug 16 To Oct15 
VATHAM-Vettunilai 
Vazharchi 
PITHAM-Thanilai Vazharchi 
2. Koothir Kaalam 
Iypasi &Karthigai 
Oct 16 To  Dec15 
VATHAM- Thanilai Vazharchi 
PITHAM- Vettunilai 
Vazharchi 
3. Munpani Kaalam 
Margazhi & Thai 
Dec16 To Feb15 
PITHAM- Thanilai Vazharchi 
4. Pinpani Kaalam 
Masi& Panguni 
Feb16 To June15 
KABHAM- Thanilai 
Vazharchi 
5. Elavenir Kaalam 
Chithirai & Vaikaasi 
April16 To June15 
KABHAM- Vettunilai 
Vazharchi 
6. Mudhuvenir Kaalam 
Aani & Aadi 
June16 To Aug 15 
VATHAM- Thanilai Vazharchi 
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THINAI (LAND): 
            Siddhars classified the lands in to five types. They are 
1. Kurunchi    - Mountain range 
2. Mullai         -Pastoral area of the forest 
3. Marudham -The fertile river bed 
4. Neidhal      -The coastal region 
5. Paalai         - Arid desert                                               
• The winter season gives good health to the man, early summer and latter rainy 
gives moderate health. Whereas early rainy and latter summer are more prone 
to diseases, that’s why siddhars called it as Aanaga kalam 
• Marudha nilam is the fertile area where no disease occurs 
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RELATION BETWEEN MUKKUTRAM, KAALANGAL AND THINNAIGAL                                                                                                                                                                         
 
  
MUKKUTRAM 
               PARUVAKALAM(SEASONS)                  
THINAI                         
Thannilai 
vazharchi 
(Accumulation) 
Vaetrunilai 
vazharchi        
(Aggravation) 
Thannilai 
adaithal             
(Alleviation) 
 
 
VATHAM 
 
 
Mudhuvenil 
kalam 
 
 
Kaar kalam 
 
 
 
 
Koothir kalam 
 
 
Vatha disease 
is more 
prevalent in 
Neidhal land 
 
 
PITHAM 
 
 
Kaar kalam 
 
 
Koothir kalam 
 
 
Munpani 
Pitha disease 
is more 
prevalent in 
Mullai land 
 
 
KAPHAM 
 
 
Pinpani 
 
 
Elavenil kalam 
 
 
Mudhuvenil 
kalam 
Kaphadisease 
is more 
prevalent in  
Kurunchi 
land 
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  UDAL VANMAI (IMMUNITY): 
            Siddhars classify Udal vanmai as three types. They are 
1. Iyarkai vanmai 
2. Kala vanmai 
3. Seyarkai vanmai 
           Since Kumbavatham patients are suffering with pain as principal symptom, we 
came to understand that it is because of alteration in Vali thathu and Vali should be 
the primary causative factor (Muthanmai kutram). It can be confirmed by the words of 
great Siddhar Therayer 
NOI KANIPPU VIVADHAM (Differential Diagnosis) 
 There are certain vatha noigal which resembles the clinical symptoms of 
Kumbavatham. They are, 
1. Sagana vatham 
2. Paanikambavatham 
3. Sirakamba Vatham 
4. Pei Vatham 
5. Kanda Kiraga vatham 
1. SAGANAVATHAM: 
   “nfSnk fG¤Â‹ ÑHiu¡F nkY« 
    bfoahd fuäu©L äfnt behªJ 
   thSnk rßubkšyh§ fd¤ÂU¡F« 
    thèg®¡F kd§f©Q ka¡fkhF« 
   VSnk Ïu©L f©Q« vç¢rY©lh« 
    V‰wkhŒ kyªjhD« ÏW»¡ fhQ« 
   njSnk bfh£odJ ngh‰ fL¡F« 
    brfd thj¤Âålª Ô®fªjhnd”. 
                                        - ô» it¤Âa Áªjhkâ 
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 Pain in the neck, Radiating pain to the shoulders and upper limb, heaviness of 
the body, mental depression, giddiness, irritation of eyes, constipation, Tingling 
sensation. 
 
2. PAANIKAMBA VATHAM: 
 “kh®¡fkhŒ  thŒÎkhŒ …. 
  eL¡fkhŒ ifæu©Lª ÂäU K©lh« 
  …………………….. Jz®¢Á a‰W 
  ghâ f«gthj¤Â‹ gh§F jhnd” 
- ô» it¤Âa Áªjhkâ 800 
Tingling sensation numbness of upper limbs  
 
 
3. SIRKAMBA VATHAM: 
 
 j«gkhŒ cÂuf©l eu«Ã‰ ò¡»¤ 
 jiynahL rhubkyhª jh¡»¥ ò¡F«..... 
 ifnahL fhèu©L« tr¡nflhF«....... 
 Á«gkhŒ jiy eL§» .... 
 Áu¡f«g thjbk‹nw br¥gyhnk” 
-  ô» it¤Âa Áªjhkâ  800 
 Stiffness of the neck, Tremor in the head and neck and diffuclty in using upper 
and lower limbs. 
 
 
 
 
4. PEI VATHAM: 
 “bg‰¿ah«bgUikah§ fhY§ ifÍ§ 
  bgUtæW beŠnrhL éuY _¡F« 
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  V‰¿ah bk¿fG¤J bk§F« g‰¿ 
  V¡fkhŒ behªJl« bg§F« Å§» 
 c‰¿ah _znt Âä®¤ bjL¤J 
  cWÂahŒ¥ Ão¡fÎbkhzhk yhF« 
 r¤ÂakhŒ thŒfrªJ ka¡fkhFª 
  jç¤Âl bt©zhJngŒ thjª jhnd”. 
       - ô» it¤Âa Áªjhkâ  800 
 Pain & Swelling in neck, Upper and lower limbs. 
 Weakness of hand muscles and difficulty in holding thing in the hand. 
 Vomitting, giddiness and swelling over the body. 
 
5. KANDA KIRAAGA VATHAM: 
  “tifahd Fuyjid¥ g‰¿ behªJ 
   khhnghL Ãlçæåš tèÍ©lh» .... 
     ...... f©l »uhf¤Â‹ g©òjhnd” 
       - ô» it¤Âa Áªjkhâ  800 
 Pain in the throat, Chest and occipital region pain, numbness Tingling 
sensation over the neck both upper limbs.  Stiffness in the neck, burning sensation in 
the eyes, difficulty in holding things in hands are the similar symptoms like Sagana 
Vatham. 
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MUKKUTRA VERUPADUGAL (PATHOGENESIS) 
 
Any Aetiology 
 
 
Vali Vitiated 
+ Azhal & Iyam 
 
 
Three dhosham affected 
V (1) : A (½) : I ( ¼ ) 
 
 
 
Udal Kattugal affected 
 
 
 
Disease 
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PINIYARI MURAIMAI (DIAGNOSIS): 
           It means the method of diagnosing the disease.           
          ‘kjpj;jplw;fUik tha;e;j 
                    khz;gupfhunky;yhe; 
             Jjpj;jpl Tzu;e;jhNdDe; 
                   Jfswg; gzpapd;wd;ik 
                  gjpj;jpl Tzuhdhfpw; 
                   gaDwhdhfhyhNd 
             tpjpj;jpL gpzpj;jpwj;ij 
                   tpsk;GJ Kjw;fz;kd;Ndh” 
- rpfpr;rh uj;jpdjPgk;- gf;fk; 3    
           The above poem describes that diagnosis is very important for the physician to 
treat the disease. 
And, 
 
§¿¡ÂÈ¢óÐ §¿¡ö Ó¾Ä¢ §¿¡ì¸È¢óÐ §¿¡Ô¾ý 
¾¡ÂÈ¢óÐ §À¡ìÌó ¾¡ÁÈ¢óÐ ¸¡Â¿¢¨Ä 
¦¿¡ó¾Æ¢Â¡ Åñ½ ¸÷Å¢ôÀ¡÷ §¿¡Â¢É÷ìÌ 
¾ó¨¾¦ÂÐ ¿üÀñÊ¾÷ 
-§¾Ãý ¦ÅñÀ¡ 
Four steps are followed in diagnosing the disease. They are, 
a. Poriyaal arithal 
b. Pulanal therthal 
c. Vinaathal 
d. Envagaithervu  
In detail, 
 
a. Poriyaal arithal: 
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                     In this the physician should carefully observe the changes that occur in 
the five sensory organs (Porigal) of the patient. 
b.Pulanal therthal: 
                 The physician carefully applies his five senses of perception, smell, taste, 
vision, touch and sound to understand the condition of the patient. 
c.Vinaathal: 
                 The physician should interrogate about the patients name, age, 
occupation,socio economic status, food habits, history of past illness, history of 
present illness, family history, marital status, menstrual history and frequency of pain. 
ENVAGAI THERVUKAL 
‘eh epwk; nkhop tpop ky%j;jpuk; 
 ehb guprkpit kUj;JtuhAjk;” 
 
      -Neha;ehly; Neha; Kjdhly;-253 
 
 
¿¡ÊÂ¡ø Óý§É¡÷ ¦º¡ýÉ ¿ø¦Ä¡Ä¢ À¡¢ºò¾¡Öõ 
¿£ÊÂ Å¢Æ¢Â¢É¡Öõ ¿¢ýÈ ¿¡ìÌÈ¢ôÀ¢É¡Öõ 
Å¡ÊÂ §ÁÉ¢Â¡Öõ ÁÄ¦Á¡Î ¿£¡¢É¡Öõ 
ÝÊÂ Å¢Â¡¾¢¾ý¨Éî Í¸Ó¼ý «È¢óòÐÀ¡§Ã 
- ¾¢ÕÁó¾¢Ãõ - 10õ ¾¢ÕÁ¨È 
                    
Nowadays advanced diagnostic tools have been developed by modern bio-
medical scientists. But Siddhars have given eight diagnostic methodological tools. 
They are called as Envagai thervu. 
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Eight fold system of clinical assessments 
Siddhars have given eight diagnostic methodological tools. They are, 
1. Naa 
2. Niram 
3. Mozhi 
4. Vizhi 
5. Malam 
6. Moothiram 
7. Naadi 
8. Parisam 
GENERAL FINDINGS: 
1. NAA: 
i. Signs and symptoms in the tongue are noted here. 
ii. Color, salivary secretion, ulcers, coating, inflammation, 
taste changes, deviation and its nature are generally noted. 
       In Kumbavatham the naa may be affected due to the pallor of the 
tongue 
2. NIRAM: 
The color of the skin is noted here. 
 3.  MOZHI: 
Character of the speech is noted, mainly uratha olli(high pitched), 
thazhntha olli(low pitched), or resembles the sound of any instrument. 
4. VIZHI: 
 Character of the eye is noted. Color, Warm, Burning Sensation, 
Irritation, Visual Perception.   
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5. MALAM: 
The stools are examined for quantity; hardening (malakattu), loose motion 
(bethi), Color and smell. 
 
    6. MOOTHIRAM: 
    A. NEERKURI: 
The urine is examined for its color, odour, volume, froth and 
weight. 
  
  B.NEIKURI 
 
‘mUe;J khwp ujKk; mtpNuhjkjha;  
  mf;fy; myu;jy;mfhyt+d; jtpu;jow; 
 Fw;wstUe;jp cwq;fp itfiw 
 Mbf;fyrj; jhtpNa fhJnga; 
 njhUK$u;j;jf; fiyf;Fl;gL ePupd; 
 epwf;Fwp nea;Fwp epUkpj;jy; flNd” 
       -rpj;j kUj;Jthq;fr; RUf;fk; - 
gf;fk;509  
                      
              The early morning urine of the patient is analyzed by dropping a drop 
of gingely oil on the surface of the urine sample. The accumulation, 
formations, changes, and dispersal under the sunlight without any external 
disturbances of the urine sample can be noted.  
• Vatha neer - The oil spreads like snake 
• Pitha neer - The oil spreads like ring 
• Kapha neer - The oil spreads like pearl 
• If the oil spreads gradually, it indicates good prognosis 
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• If the oil spreads fast or gets mixed completely with urine or sinks in 
urine, it suggests bad prognosis. 
7. NAADI: 
             Naadi is a Unique Siddha Pulse reading method and it should be felt 
and not read. Different gaits of Vazhi , Azhal, Iyam  like branching, jumping, 
mixing, rotating and compression can be identified. 
NAADI NADAI: 
 
      
 
 
 
 
 
  
 ‘ghu;f;fNt ngz;fSf; fplJgf;fk; 
     gjpthfg; ghu;j;jplNt gfugf;NfSk; 
     fhu;fNt thjkJ ru;g;gk; Nghyha; 
 
IDENTIFICATION 
(FINGER) 
 
INDEX 
 
MIDDLE 
 
RING 
 
STRENGTH (IN UNIT) 
 
1 
 
1|2 
 
1|4 
 
 
PATTERN 
 
 
 
MALE 
 
Hen 
 
Tortoise 
 
Snake 
 
FEMALE 
 
Snake 
 
Frog 
 
Swan 
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     fdkhd gpj;jkJ jtis NghyhQ; 
      Nru;f;fNt iaankd;w ehbjhDQ; 
     rpWeilah td;dk; Nghw; nropg;gha;f; fhDk;” 
                        -gjpnzd; rpj;ju; ehbrhj;jpuk; (gupG+uz ehb)-  
gf;fk;2 
Vatha naadi: 
     ‘thjnkDk; ehbaJ Njhd;wpw; rPjk;…... 
             jpus;thA #iy typf;fLg;Gj; jpiu” 
- rjf ehb 
- Neha;ehly; Neha; 
Kjdhly;253 
Vatha pitham: 
         ‘jpUj;jkhk; thjj;NjhNl j_q;nfhL gpj;jQ; Nrupy; 
             nghUj;Jfs; NjhWk; nehe;J NghjNt gpbf;FQ; #iy” 
 - Fzthfl ehb(mfj;jpau;)-
ghly; 26 
 In Kumbavatham the Naadi can be vatha naadi  and vatha pitham naadi 
8. PARISAM:  
Observations as touch, temperature, sensory impairment, masses, nodes, 
swelling, and texture of the skin, pain, hardness, edematous, and dullness shall 
be noted. 
 
LINE OF TREATMENT: 
 
1. To bring the three Kutrams in equilibrium 
2. Medicines (Int ) 
3. Diet and advises  
4.  Thokkanam, Otradam, Patru  
5. Yoga  
6. Suttigai 
7. Kanmanivarthy 
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1. Since Kumbavatham is belongs to Vatha disease, purgative is given to 
balance the Vatham. 
 
‘tpNurdj;jhy; thjk; jhOk;”;  
2.MEDICINE:    Kanthaga Parpam: 
- 200 mg, Twice Daily. 
- With Honey. afterfood 
 DURATION OF TREATMENT: 
            20 days medicine with ichapathiyam, 
3. DIET AND ADVICES: 
Pathiyam (Diet Regimen) 
 During the course of treatment according to the nature of illness and the 
drug administered.  The patient were advised to follow certain special dieting 
methods called “PATHIYAM”.  The importance of Pathiyam is clearly 
mentioned by Theraiyar as follows: 
  “g¤Âa¤Âdhny  gyD©lhF«  kUªJ 
    g¤Âa§fŸ nghdhš gy‹ nghF« - g¤Âa¤Âš 
    g¤Âank bt‰¿ jU« g©ojUfhjèdh‰ 
    g¤Âank cWÂba‹W gh®”. 
- njiua® bt©gh g¡f« 
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Three types of Pathiyam are commonly told.  They are Kadum 
Pathiyam, Miga Kadum Pathiyam, Ichcha Pathiyam and Uppilla Pathiyam (salt 
free dieting) also mentioned in ancient + Siddha literatures especially for the 
mercurial preparations of drugs. 
Pathiam is sensitive to the body towards good drug response and Cope 
up with the drug avoiding manifestation of adverse effects. 
Vali (të  ) Roga Pathiyam: 
  “ò ëJt®  éŠR§  f¿ah‰  óç¡F« thj«’’ 
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- f©Qrhäaf« 
 Tamarind and Astringent increase Vali (të) .  So kumba vatham 
patients were advised to avoid these things. 
In Pathartha Guna Chindamani 
  fLf e‰¿y¤ bj©bzŒ Tœgh©l§fŸ fliy 
  tLfjh»a bj§fkh tU¡if e‰fha« 
  koéyhj btŸSŸë bfhŸ òifæiy kJbg© 
  ÏlWghfnyh  lf¤Â Ú¡»lè¢ rhg¤Âa«” 
- gjh®¤j Fz Áªjhkâ 
Ï¢rhg¤Âa« - Ú¡F« bghU£fŸ 
  
 fLF, vŸbeŒ,  fèahzórâ, fliy, nj§fhŒ, kh§fhŒ, gyh, 
fha«, ó©L, bfhŸ, òifæiy, bg©fŸ, ghfš, mf¤Â Kjèad. 
 
 
 
 
tënehahs®fë‹ g¤Âa«: 
 
  “br§fGÚ® nfh£lªnj‹ äsF ešby©bzŒ 
    j§FbgU§ fhaª jGjhiH ba§bf§F§ 
    T£L ÁW K¤JbeŒ nfhÂ tHªÂitfŸ 
    th£L kây¤ij kÂ”. 
-gjh®¤j Fz Áªjhkâ  
g.369 
  “kh£L gw§» t§f kh‹.. ... 
   thjnj »®¡»urK« it”. 
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br§fGÚ®, nfhZl«, bgU§fha«, nj‹, äsF, ešby©bzŒ, jGjhiH, 
Á‰whkz¡F beŒ, cSªJ, fšahzórâ, tGjkd§fhŒ, 
btŸstu¡fhŒ, fhuh¡fUiz, F¥ignkå, K‹id, Miu, ešntis, 
kâ¤j¡fhë, ahid beUŠÁš, KRKR¡if, nfhit, griy, 
f¤jç¡fhŒ, KU§if ÃŠR, ghfš ÃŠR, fh£L¡ fUiz. 
 
4. THIOKKANAM (MASSAGE THERAPY) 
Thokkanam is systemic manipulation of the body parts by the physician. 
 “bjh¡fz¤Âdh èu¤j«  njhš Cåit  f£F 
  ä¡f rÎ¡»a« rÛuD« ngh« -  bkŒ¡fÂf 
 ò£oÍw¡f« òz®¢Á æit fÂ¡F« 
 g£l  miy¢ryW«  gh®”. 
- gjh®¤j Fz Áªjhkâ 
Thokkanam acts directly on vascular system, nervous system, lymphatic 
and muscuto skeletal system and brings the affected body to normal condition  
physically and mentally.  It also gives sense of well being, gives  a good sleep 
and increase vital power and also provides relaxation. 
Vali (të) diseases are relieved specially by Thokkanam by below 
quotos,  
  “k¤jdkh»a bjh¡fz¤Â‹ braš tF¥ghnd- rjh 
   ã¤jK« thj« Ãâ¤j Ãâ¥ig brF¥ngnd. 
            -    nj.kfh.fçrš 
 In nine types of Thokkanam.  These are all the two methods used in 
kumba vatham 
1. Pidiththal (effleurage and pettriasage)  
2. Izhuththal (Traction)  
 In Pidiththal, strokes are slided smoothly and by kneeing. In Izhuththal 
traction like method is performed. 
Physical:  
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  Rubbing of the body produces heat and increases blood circulation.  It 
gives more oxygen to all parts of the body & flushing out waste gases and 
toxins. 
Phyche :  
  Through touch, massage works on the nervous system and increases the 
circulation of growth hormones.   
 Massage gives relief from headache, muscleache anxiety, weakness, 
irritability, feelings of insecurity and in the Non-drug method for sleep.  
 Massage also increases the production of WBC antibodies & helps in 
defense mechanism to increases the immunity. 
 
 
5. YOGA THERAPY. 
 Yoga is India’s unique contribution to the world.  Yoga therefore is an 
art which brings an incoherent and scattered mind to a reflective and coherent 
state.  Thirumanthiram is the oldest text in Yoga.  It enumerates the means of 
Yoga as”Astanga Yoga” or stages of Yoga for the realization of the soul. 
They are: 
Iyama   : Observances 
Niyama  : Restraints 
Asanas  : Postures 
Pranayama  : Rhythmic Control of breath 
Prathyahara  : Withdrawals and emancipation of the mind 
from the domination of senses and exterior 
objects  
Dharana  : Concentration 
Dhyana  : Meditation 
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Samathi  : A state of superior consciousness brought 
about by profound meditation in which the 
individual aspirant becomes one with cosmic 
consciousness. 
 Yoga has a massage for the human body, mind and also for the human 
body, mind and also for the human soul. 
A.Therapeutic Yoga: 
 It is basically a system of self treatment.  Yogasanas are reliable 
supportive therapy or sometimes plays main part of the treatment of Vali 
diseases. The yogasanas are useful not only to revive the body but also 
strengthen the nervous system, locomotor and digestive systems.  It regenerate 
the endocrine system.  They bring the human body under the complete control 
of mind. 
 The following asanas are advised to the patients to relive from the 
symptoms of kumbavatham. 
1. Pujankaasana: 
 Helps in keeping the dorsal spine elastic and strong.  Back ache due to 
over strain can be relieved.  Helps in considerable reduction of abdominal fat. 
2. Maharasana: 
It gives complete relaxation to the muscles and is useful in Hypertension 
Insommia etc. 
3. Savasana: 
 For sound sleep and restoring mental peace.  These asanas can be done 
after the neck pain is reduced considerably with drug treatment. 
B. Piraanaayaamam: 
 Piraanaa means vital force or breath.  Aiama means the control of the 
piraanan. Regular practice of  Piraanaayaamam and Asanaas combined with 
control of the mind they will combat negative elements such as ignorance, 
Lazziness, inertia and over excitement as well as increasing the will power. 
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 The main object of piraanaayaamam is to acquire mastery of the vital 
force acting with in the body.  It improves the functions of Piraanan, nourishes 
the body cells, purifies blood and tones up nerves. 
 In cases of Kumba Vatham, Piraanaayaamam corrects the disturbed 
piraanan tones up the nerves of affected area. 
C. Thiyanam (Meditation): 
 Thiyaanam the continuous  flow of the mind  towards, “Aathma” 
through the total exclusion of all ideas foreign to it.  The principal disciplines 
for thiyaanam are Iyamam and Niyamam. 
Iyamam –  Includes non violence, truthfulness, non stealing, sensation of all 
women as mother’s and sisters except wife and not speaking and 
doing useless matters. 
Niyamam- It means outer and inner purity, contentment, austerities, study of 
scripture and devotion to god.  By Thiyanam man can know 
himself. 
 So it is helpful in stressful mental conditions and gives relaxation to 
mind.           
 In cases of kumba vatham, Thiyaanam gives complete rest to the body 
including neck and provides relaxation. 
6. SUTTIGAI:- 
 It is the process to give heat in some particular varma part of the body 
for the curation of the disease. 
 In Varma Vidhi : 
ghçr thjŠ r‹å thj«... 
kUÎbk© g¤J eh‹F thj¤Â‰ »u£ir nf©ä‹ 
bghUéyh Î¢Á ÛÂ‰ òf‹¿L FW¡F¢ NL« 
jUbe‰¿ be¿æ‰ bgh£Lª jh‹ Rl¢ rhye‹nw 
       ghlš 32 
 
rhynt Ãlç_£o‹  nkšneh¡» Ãiwngh‰NL« 
nkYK‹ if¡F nkny æu©ol« bgh£L¢ NL«. 
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       ghlš 23 
 
For curation of vadha diseases there is applying of suttigai on the head, 
forehead, occipital region, forearm with Eratchai instrument.  
 
7.  KANMA NEEKKAM (EXPIATION) 
 Kanmam means the deed which are committed by an individual in this 
and previous births .  So, he must expiate it to get better relief before the 
treatment. 
  “eèahny tªj f‹k« Ôubt‹whš 
  e‹ku§fŸ njh¥ò eilrhiy it¤jš  
  bjëthd »zW bt£lš Fs§fŸ bt£lš  
bjŒ¥gjy« nfhæš f£l¤ ÔU« ghL 
  vëjhd ghyf®¡ fhguz Ûjš 
  v‹gbj‹w thjbkšyh élªJ nghF« 
  gêahd nehŒ tªjh è¥gona brŒJ 
  gçthf it¤Âa¤ij¥ ÃwF brŒna” 
-  mf¤Âa® f‹k fh©l« 300 
 Planting the young trees, establishing the gardens laying roads and 
pathways, Digging wells, ponds for public use, constructing temples and 
Donates to poor children must be done. 
 
 PATHIYAM AND APATHIYAM: 
 
A. Pathiyam(diet): 
Diet: 
The food must bring the vatha under the control  
Food like kanji, tender vegetables of brinjal, beans, fig and some greens which 
is useful in vatha diseases. 
In dal types only dhoor dal is preferable. 
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B. Apathiyam(Avoid): 
 In vegetables which is rich in water content like Surai, poosani, 
vellari, pudalai, peerku. 
 In grams like karamani, ulunthu, kollu and mustard 
 Underground tubers. 
 
 ADVICE: 
  Avoid sleeping in open or moisturised air. 
 
 PREVENTION: 
  Balanced & Low fat diet 
 Regular exercise 
 Suriya namesakaram 
 Oil bath twice in a week 
 Avoid Junk foods 
 Avoid tobacco, Alcohol 
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MODERN ASPECT 
      Periarthritis or Frozen Shoulder 
DEFINITION 
               Periarthritis of the shoulder is a chronic, retrograde and 
inflammatory disease of the shoulder joint, capsule and the soft tissues 
surrounding it. This pathology is mostly due to exposure to cold, trauma, or 
chronic strain of the shoulder. The main clinical manifestations are soreness 
and dysfunction of the shoulder. The disease is usually found in patients 
above the age of 50.  
SYMPTOMS 
              Pain is the most obvious symptoms, the gradual emergence of a 
shoulder at the pain, and body movements, gestures as significant. With the 
extended duration of pain was expanded and involved the middle upper arm, 
and shoulder joint with limitation of activity. the extent and nature of pain big 
difference, or dull, or knife-like, For increased range, there are severe sharp 
pain occurs. severe limb can not comb the hair, face wash, and buckle belt. 
night stand movement because of pain in the shoulder and wake up. This can 
cause pain, persistent muscle spasms, muscle cramps and some light, some 
heavy, pain and muscle spasms can be confined to the shoulder, you can also 
up after radiation to the head, wrist and fingers reach down , and some 
radiation to the shoulder blades back, forward to the chest; also some radiation 
to radiate into the triceps or deltoid, biceps direct radial forearm wide range of 
frozen shoulder tenderness. due to illness in different parts of tender points and 
tenderness to the degree of inconsistency, the patient initially still capable of 
that pain point, late expanded to feel pain in the humerus. 
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Shoulder Joint Anatomy 
The Shoulder Joint 
 This is a multiaxial ball and socket type of synovial joint that permits 
a wide range of movement. However, mobility is gained at the expense of 
stability. The human shoulder is the most mobile joint in the body.This 
mobility provides the upper extremity with tremendous range of motion such as 
adduction, abduction, flexion, extension, internal rotation, external rotation, 
and 360° circumduction in the sagittal plane. Furthermore, the shoulder allows 
for scapular protraction, retraction, elevation, and depression. This wide range 
of motion also makes the shoulder joint unstable. This instability is 
compensated for by rotator cuff muscles, tendons, ligaments, and the glenoid 
labrum.. 
 The shoulder or pectoral girdle is composed of the bones that connect 
the upper extremity to the axial skeleton. Two bones comprise the shoulder 
girdle. These are the clavicle and scapula. 
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SKELETAL ANATOMY OF THE SHOULDER 
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Osteology 
Scapula 
 The scapula is a triangular-shaped bone that functions mainly as a site 
for muscle attachment. Four rotator cuff muscles that act on the shoulder take 
their origin from the scapula. These are the supraspinatus, infraspinatus, teres 
minor, and subscapularis 
 Additionally, the trapezius, serratus anterior, rhomboids, and levator 
scapulae insert on the scapula and are responsible for scapular mobility and 
stability. The scapula is freely moveable, because it is suspended by these 
muscles. The scapula has 4 processes, the spine, the acromion, the coracoid, 
and the glenoid. The glenoid cavity (or, alternatively, the glenoid fossa) is set 
on the expanded aspect of the lateral angle of the scapula. The glenoid cavity is 
an irregularly shaped oval and has been compared to an inverted comma shape. 
It articulates with the head of the humerus, forming the glenohumeral joint, 
which serves as the main joint of the shoulder. 
Clavicle 
 The clavicle is an S-shaped bone that forms the anterior portion of the 
shoulder girdle that keeps the arm away from the trunk, allowing it to move 
freely. The clavicle has 2 articulations, the sternoclavicular joint and the 
acromioclavicular joint. The sternoclavicular joint is formed by the medial 
aspect of the clavicle articulating with the manubrium of the sternum. This is 
the only skeletal connection between the axial skeleton and the upper 
extremity. Furthermore, the clavicle provides protection for the subclavian 
artery, subclavian vein, and brachial plexus posteriorly and inferiorly. 
Humeral head 
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 The proximal articular surface of the humerus is termed the humeral 
head. The humeral head articulates against the shallow glenoid cavity. Only 
25% of the humeral head surface makes contact with the glenoid cavity. The 
glenoid labrum, a fibrocartilaginous ring attached to the outer rim of the 
glenoid cavity, provides additional depth and stability. 
Articulations 
Sternoclavicular joint 
 The sternoclavicular joint is the sole connection between the axial 
skeleton and the upper extremity. The sternoclavicular joint allows 30-35 º of 
upward elevation, 35 º of anteroposterior movement, and 44-50 º of rotation 
about the long axis of the clavicle. 
Acromioclavicular joint 
 The acromioclavicular (AC) joint is the only articulation between the 
clavicle and scapula. It is formed by the distal clavicle articulating with the 
acromion of the scapula. Little motion exists in this joint. The AC joint is an 
encapsulated diarthrodial joint held together by its joint capsule and the 
coracoacromial ligaments: the trapezoid and conoid ligaments. 
Glenohumeral joint 
 The glenohumeral joint is the main articulation of the shoulder joint. It 
is the multiaxial ball-and-socket synovial joint formed by the articular surfaces 
of the glenoid cavity and the head of the humerus. The glenoid cavity depth is 
increased by a rim of fibrocartilage that surrounds it. This rim of fibrocartilage 
is the glenoid labrum. 
Labrum 
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 The glenoid labrum is a ring composed of mostly dense fibrous tissue. 
The average depth of the glenoid cavity is 2.5 mm, but the labrum serves to 
increase this depth. Although the labrum increases the depth and volume of the 
glenoid cavity, it does not seem to increase the stability of the glenohumeral 
joint. 
 
 
Ligaments 
Coracoclavicular 
 The conoid and trapezoid ligaments comprise the coracoclavicular 
ligaments (CCLs) . They function to maintain the articulation of the clavicle 
with the coracoid process of the scapula. Studies have concluded that the 
coracoclavicular ligaments are the primary restraint to superior and posterior 
clavicular dislocation. 
Glenohumeral 
 Three glenohumeral ligaments exist: (1) the superior glenohumeral 
ligament (SGHL), (2) the middle glenohumeral ligament (MGHL), and (3) the 
inferior glenohumeral ligament (IGHL). The SGHL has a variable origin and 
inserts on the humerus near the lesser tubercle; this ligament resists inferior 
translation of the humeral head in the adducted shoulder. The MGHL originates 
from the labrum and inserts on the humerus medial to the lesser tubercle; this 
ligament resists inferior translation in the adducted and externally rotated 
shoulder. The IGHL originates from the labrum and the adjacent glenoid neck, 
inserts on the anatomic neck of the humerus, and resists humeral head anterior 
and posterior translation. Furthermore, the IGHL is the primary restraint to 
inferior dislocation in the abducted shoulder. 
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Coracohumeral 
 The coracohumeral ligament (CHL) originates on the base and lateral 
border of the coracoid process of the scapula and inserts on the greater tubercle. 
The biomechanical function of this ligament is not fully understood; however, 
it appears to have suspensory function of the humeral head. 
 
 
Rotator cuff 
 The supraspinatus, infraspinatus, teres minor, and subscapularis muscles 
comprise the rotator cuff . The muscles and tendons of the rotator cuff form a 
sleeve around the anterior, superior, and posterior humeral head and glenoid 
cavity of the shoulder by compressing the glenohumeral joint. In addition to 
stabilization, the rotator cuff provides the shoulder with tremendous mobility. 
 
 
 
 
Table 1. Origins, Insertions, Actions, and Nerve Supplies of the Rotator Cuff 
Muscles. 
Muscle Origin Insertion Action Nerve Supply 
Supraspinatus Supraspinous 
fossa 
Greater 
tubercle of 
humerus 
Abduction of the 
arm to 
approximately 30 
º 
Suprascapular 
nerve 
Infraspinatus Infraspinous Greater External Suprascapular 
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fossa tubercle of 
humerus 
(lateral)rotation 
of the arm 
nerve 
Teres minor Upper 2/3 of the 
lateral border of 
the scapula 
Greater 
tubercle of 
humerus 
External (lateral) 
rotation of the 
arm 
Axillary nerve 
Subscapularis 
 
 
Subscapular 
fossa on the 
anterior surface 
of the scapula 
Lesser 
tubercle of 
humerus 
Internal (medial) 
rotation of the 
arm 
Upper and 
lower 
subscapular 
nerves 
 
Bursae around the Shoulder Joint 
The Subscapular Bursa  
• This bursa is located lies between the tendon of the subscapularis 
muscle and the neck of the scapula. 
• The bursa protects this tendon where it passes inferior to the root of the 
coracoid process and over the neck of the scapula. 
• It usually communicates with the cavity of the shoulder joint through an 
opening in its fibrous capsule; thus it is really an extension of the cavity 
of the shoulder joint. 
The Subacromial Bursa  
• This is a larger bursa that lies between the deltoid muscle, 
the supraspinatus tendon, and the fibrous capsule of the shoulder joint. 
Its size varies, but it does not normally communicate with the cavity of 
the shoulder joint. 
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• The subacromial bursa is located inferior to the acromion and 
the coracoacromial ligament, between them and the supraspinatus 
muscle. 
The subdeltoid bursa 
• The subacromial bursa lies on the superior aspect of the 
supraspinatus tendon .  
• The bursa acts to cushion and reduce friction during motion 
between the overlying bone of the acromion and the soft rotator 
cuff muscles below.  
• It often extends laterally to be continuous with the subdeltoid 
bursa. 
 
 
 
 
 
Blood Supply to the Shoulder Joint 
• The articular arteries to the shoulder joint are branches of the anterior 
and posterior circumflex humeral arteries from the axillary and the 
suprascapular artery from the subclavian. 
 Nerve Supply of the Shoulder Joint 
• The articular nerves are branches of the suprascapular, axillary, and 
lateral pectoral nerves. 
Stability of the Shoulder Joint  
• The free movement of this joint leads to instability. 
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• The shallowness of the glenoid cavity and the laxity of the fibrous 
capsule also result in a considerable loss of stability. 
• The strength of the joint results mainly from the muscles that surround 
it, particularly the rotator cuff 
muscles (supraspinatus, infraspinatus, teres minor andsubscapularis). 
• These four scapular muscles, joining the scapula to the humerus, are 
attached near the articular areas of the articulation and are closely 
related to the fibrous capsule of the joint. 
• Although they have separate functions, the rotator cuff muscles work 
as a group in holding the head of the humerus in the glenoid fossa. 
                                
• The supraspinatus muscle and the coracoacromial arch guard the 
shoulder joint superiorly; the infraspinatus and teres minor 
muscle stabilise it posteriorly; and the subscapularis muscle protects it 
anteriorly. 
• There is no tendinous support of the shoulder joint inferiorly; 
consequently, this is where it usually dislocates. 
Movements of the Shoulder Joint  
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• This joint has more freedom of movement that any other joint in the 
body. 
• This freedom results from the laxity of the joint's articular capsule and 
the large size of the humeral head compared the small size of the 
glenoid cavity. 
• The shoulder articulation is a multiaxial ball-and-socket joint that 
allows movements around three axes and permits flexion-extension, 
abduction-adduction, circumduction, and rotation. 
• In circumduction, the distal end of the humerus describes the base of a 
cone, the apex of which is the head of the humerus. 
 
 
 
Natural Variants  
Labrum, clavicle, and scapular notch variability 
Several minor anatomic variations exist in the attachment sites, size, and 
histologic composition of the labrum. These variations are not considered 
pathologic. 
Variations in the shape of the clavicle are considered normal and are not 
usually pathologic. These variations may range from an almost straight bone to 
one with exaggerated curves. Another variation of the clavicle that is present in 
6-10% of the population is termed the canalis nervi supraclavicularis. In this 
variation, a foramen forms through the clavicle, and the medial supraclavicular 
nerve passes through this accessory osseous canal. 
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The scapular notch varies in size and shape. The notch is bridged by the 
superior transverse scapular ligament. This ligament ossifies in 10% of 
patients, producing a bony foramen for the suprascapular nerve. 
Pathophysiological Variants 
Acromion morphology variability 
Bigliani et al separated acromions into 3 categories based on their shape and 
their correlation with rotator cuff tears , as follows: 
• Type I: Flat undersurface of the acromion (This type has the lowest risk 
for impingement syndrome.) 
• Type II: Curved undersurface of the acromion 
• Type III: Hooked undersurface of the acromion (This type has the 
highest correlation with subacromial pathology.)Acromion types. 
 
 
Acute Shoulder Injury 
Glenohumeral dislocation 
The glenohumeral joint is the major articulation of the shoulder joint. 
Dislocation of the glenohumeral joint occurs when the humeral head is moved 
out of contact with the glenoid cavity. Almost 85% of shoulder dislocations are 
anterior dislocations.An anterior dislocation is likely to occur when the arm is 
abducted, extended, and externally rotated. Posterior dislocation of the 
glenohumeral joint is rare but is more likely to occur when the arm is adducted 
and internally (medially) rotated. Violent muscle contractions during a seizure 
or electrocution may also produce a posterior glenohumeral dislocation. 
Acromioclavicular joint sprain or dislocation (shoulder separation) 
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The AC joint is frequently injured in athletes. The injury commonly occurs 
when direct force is applied to the acromion with the arm adducted. The force 
causes the acromion to suddenly move inferiorly, which first strains or tears the 
AC ligaments and may subsequently strain or tear the coracoclavicular 
ligaments as well. 
Rotator cuff tear 
Rotator cuff tears are common injuries; such a diagnosis indicates one or more 
of the rotator cuff tendons have torn. The injury may be result of chronic 
impingement and tendonitis that has progressed, or it may refer to an acute 
injury such as a fall or direct trauma. People with a rotator cuff tear may 
experience pain and weakness in their shoulder. 
Subacromial/subdeltoid bursitis 
Inflammation of the bursa is relatively rare but may occur. 
 
 
Labral tear 
People that participate in repetitive overhead activities such as swimming or 
throwing a ball have an increased risk of labral tear. A labral tear may be 
asymptomatic or manifest as shoulder instability, pain, or crepitus. 
Glenohumeral osteoarthritis 
Glenohumeral osteoarthritis is a slowly progressive arthropathy that is caused 
by the loss or destruction of articular cartilage. This is usually a condition that 
develops as people age and their articular cartilage wears down. However, it 
can also be due to trauma such as a humeral head fracture, shoulder dislocation, 
or rotator cuff tendon tears. 
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Adhesive capsulitis 
Primary adhesive capsulitis causes a painful and stiff shoulder usually without 
a known inciting event. The stiff glenohumeral joint is most likely a result of 
chronic inflammation and fibrosis. Adhesive capsulitis has 3 phases, and each 
phase typically lasts 4-6 weeks, with wide variability. The 3 phases are as 
follows: 
1. "Freezing phase": Spontaneous pain and stiffness in the shoulder 
2. "Frozen phase": Increased stiffness and stable or decreased pain 
3. "Thawing phase": Increased range of motion and decreased pain. 
INVESTIGATION  
Investigations for Periarthritis 
Periarthritis is mostly diagnosed clinically, ie from what the patient tells 
us and what the doctor finds in the examination. 
However, investigations are performed to exclude other diagnoses and 
to identify more closely the exact nature of the problem. 
X-rays 
X-rays of the shoulder are normal in appearance, with perhaps some loss 
of bone density due to not using the area. 
OTHER INVESTIGATION: 
Arthrogram 
This investigation involves the injection of dye into the joint, a special 
dye which shows up on an xray. The dye fills the joint and so shows up a 
normal or a tight and contracted joint space. In frozen shoulder the space of the 
joint is much reduced and this shows on the xray film. 
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MRI scanning 
This has not shown up any significant or diagnostic changes which 
would be of help. 
 C.T. scan:  
  Confirms degenerative changes  
Arthroscopy 
Arthroscopic examination (keyhole surgery) of the shoulder joint allows 
the surgeon to see directly what has happened to the tissues inside the joint. 
The major abnormal finding is a scarring up of one of the areas in the front of 
the shoulder joint. 
A fold of the shoulder capsule in the armpit area is also contracted up 
but there are no adhesions as such in the joint. A tightening up of a major joint 
structure, the coracohumeral ligament, may be the main lesion in people with 
frozen shoulder.  
 
 
 
Exercise for shoulder: 
• Arms lift forwards up and down 5 times increase to 7 – 10 times. 
• Arms lift side ways, up and down – 5 times increase to 7 – 10 times. 
• Arms life forwards, part and together – 5 times increase to 7 – 10 times. 
• Fingers on the shoulder with elbow bent: 
       a.  elbows circling forwards, upwards, backwards & downwards – 5 
times increase to 7 – 10 times. 
       b.    Elbows circling backwards, upwards, forwards & downwards - 
5 times increase to    7 – 10 times. 
• Shoulders bracking – 5 times increase to 7 – 10 times. 
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• Right hand meeting left hand at the back (Right hand to be carried above 
the Right                shoulder, left hand carried from the left side at the 
back and try to touch the right hand. 
• Repeat the left hand carried above the left shoulder and the right hand 
turned in carried from the side of trunk – 3 times each side, increase to 5 
– 7 times. 
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Trial drugs 
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 LITERATURE REVIEW OF TRIAL DRUGS 
¸ó¾¸õ : 
 
Chemical Name   : Sulphur  
Í¨Å   :  ¨¸ôÒ ,  ÐÅ÷ôÒ  
                                                     
¦ºö¨¸: 
• ¸¢ÕÁ¢¿¡º¢É¢  (Anti-dote) 
• Å¢Â÷¨Å ¦ÀÕì¸¢     (Diaphoretic) 
• ¯¼ø§¾üÈ¢  (Nutrient) 
• À¢ò¾É£¨Ã «¾¢¸ôÀÎòÐõ ¦ºö¨¸Ôõ  (Chologogue) 
• ÁÄÁ¢Çì¸¢î ¦ºö¨¸Ôõ   (Laxative) 
Ì½õ   (Properties)  : 
  
 
                    ¦¿øÄ¢ì¸¡öì ¸ó¾¢ìÌ ¿£ûÀ¾¢¦½ý Ìð¼Áó¾õ  
                    Åø¨Ä ¸Å¢¨ºÌýÁ Å¡Ô¸ñ§½¡ö - ¦À¡øÄ¡  
                    Å¢¼ì¸ÊÅý §Á¸§¿¡ö Å£ÚÍÃõ §À¾¢  
                    ¾¢¼ì¸¢Ã¸ ½£¸Àõ§À¡ó  §¾÷ 
- Ì½ôÀ¡¼õ ¾¡Ð-º£Å ÅÌôÒ 
Àì¸õ 303 
ÁÕ¾õÀð¨¼  :   
 
Botanical Name  :  Terminalia arjuna 
Family         :  combretace 
À.¯    : Àð¨¼   
Í¨Å   : ÐÅ÷ôÒ 
¾ý¨Á  : ¾ðÀõ 
À¢¡¢×   : ¸¡÷Ôò 
 
¦ºö¨¸: 
 ¯ÃÁ¡ì¸¢  (Tonic) 
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 ¾ÁÃ¸¦ÅôÀÓñ¼¡ì¸¢  (Cardiac stimulant) 
 
Ì½õ   (Properties) : 
 
 
                    µ¾¦ÁÛ ¿£¡¢Æ¢¨Å §Â¡ðÎõ À£Ã§Á¸í 
                    ¸¡¾¦ÁÉ §Å¡¼ì ¸¼òÐí¸¡ñ - §À¡¾  
                    ÁÂì¸ ¦Á¡Î¾¡¸ Á¡È¡î ÍÃò¾¢ý  
                    ¾Âì¸ÁÚìÌõ ÁÕ¾ï º¡üÚ  
                                                                               - «¸ò¾¢Â÷ Ì½Å¡¸¼õ 
 
±ÖÁ¢î¨º  :                  
 
 
          Botanical Name     :  citrus limon 
Family         :  Rutaceae 
À.¯    :    ÀÆõ  
           Í¨Å   :  ÒÇ¢ôÒ   
¾ý¨Á  :  ¦ÅôÀõ 
À¢¡¢×   : ¸¡÷ôÒ 
 
¦ºö¨¸ :  
 
          ÌÇ¢îº¢Ôñ¼¡ì¸¢   (Refrigerant) 
 
 
Ì½õ   (Properties) : 
 
               ¾¡¸õ Ì¿¸§¿¡ö ¾¡Æ¡Š º¢Ä¢À¾§¿¡ö  
               §Å¸í¦¸¡û  ¯ýÁ¡¾õ Å£ÚÀ¢ò¾õ - Á¡¸ñ§½¡ö  
               ¸ýÉ§É¡ö Å¡ó¾¢Ôõ§À¡í ¸ðÎÅ¡ ¾¢ò¦¾¡Æ¢Ä¢ø   
               Áý¦ÉÖÁ¢Š ºí¸É¢¨Â Å¡úòÐ   
                           - «¸ò¾¢Â÷ Ì½Å¡¸¼õ 
 
 
 
 
76 
 
 
                                  
 
                                                    
 
 
 
 
                                   
        
                                                            
 
 
                                             
 
 
 
 
 
 
 
 
      
A AGA  
  PURIFIED 
 
 
77 
 
 
 
 
 
 
Materials & 
Methods 
 
 
 
 
 
 
 
78 
 
 
METERIALS AND METHODS  
PROTOCOL 
Introduction: 
The clinical trial for PERIARTHRITIS was decided to be conducted as 
an open label study. 
Data collection: 
• Literary evidence from various 
• Siddha books 
• Medical journals 
• Internet 
Trial spot: 
The entire study was conducted on patients on attending the OPD and IP 
of Government Siddha Medical College, Aringnar Anna Hospital Of Indian 
Medicine Campus , Arumbakkam, Chennai- 106 , during the period 2010-2013. 
Population: 
   It is usually occurs to people who are above the age of 50.To estimate 
the Periarthritis has a 2% prevalence in general population. 
 
The population consists of periarthritis patients satisfying the inclusion 
and exclusion criteria mentioned below.  
 
INCLUSION CRITERIA 
1. Age:  Between 45 - 60 years. 
2. Willing to give specimen of blood for investigation when required. 
3. Willing to attend the OPD once in 7 days 
4. Adhere to protocol requirements with written informed consent. 
                                                                                    
EXCLUSION CRITERIA: 
1. Injury 
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2. Diabetes Mellitus 
3. Hemiplegia  
4. Cardiac ischemia 
5. Gall bladder stone 
 
Duration of Treatment: 
 20 days. 
Patients were followed under the guidance and supervision of the HOD, 
Professor, Reader, Lecturer and Asst. Lecturer of the Maruthuvam P.G 
Department, GSMC, Chennai-106. 
40 patients were selected and carefully studied for their history, clinical 
examinations, investigations and management. 
 
Evaluation of Clinical Parameters: 
 
The history includes past, personal, family, occupation, dietary habits, 
Seasonal history, and associated history. 
 
Investigations: 
 Blood 
 TC, 
 DC,  
 ESR,  
 HB,  
 Blood sugar, 
 Blood Urea  
 Serum Cholesterol  
 Serum Creatinine 
 Urine:       
 Albumin 
 Sugar 
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 Deposit  
 X- ray: 
 Shoulder joints 
    Antroposterior (AP ) view  & Lateral view 
 
Investigations Based On Siddha System: 
1. Envagai Thervu:        
Na, Niram, Mozhi, Vizhi, Sparisam, Naadi, Malam,  
Moothiram 
2. Neerkuri: 
Niram, Manam, Eadai, Nurai, Enjal 
3. Neikuri :  
      
A case sheet format was prepared on the basis of the Siddha 
methodology example envagai thervvugal, mukkutram, nilam, kaalam, udal 
thathugal, including neerkuri and neikuri. Individual case sheet was maintained 
for each patient at outpatient department. 
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Trial Drug: 
Drug:  KANTHAGAPARPAM : 
Reference :  Anupoga vaithiya navaneetham part- 6 
  
Ingredients: 
1. Kanthagam (sulphur)  
2. Marutham pattai ( Terminalia arjuna ) 
3. citrus limon 
Procedure: 
• 35gm of kanthagam is taken and kept it in lemon juice for 60 
nazhigai(24 hr) and dried, and maruthambattai ash (84gm) is taken 
.  
• The pudam is done by 100 palam dried varati 
Dosage:   
200 mg  b.i.d  after food 
Adjuvant:   
Honey  
Duration:   
20 days  
Indication: 
 
 80 types of vatha disease 
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RESULTS AND OBSERVATIONS: 
 
The factors considered for the purpose of the study comprised of the following: 
 
 Age Distribution 
 Thinai 
 Paruva kaalam 
 Occupational status 
 Socio economic Status 
 Food habits 
 Personal habits 
 Symptoms 
 Classifications of results according to Vali, Azhal & Iyyam 
 Udal kattugal 
 Enn vagai thervu 
 Naadi 
 Classification on the basis of Neikkuri 
 Clinical progress 
 Results after treatment. 
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Age Distribution:- 
 
Sl.NO 
 
     Age        No.of patients/40 Percentage 
 
   1. 
 
41-50 
 
                       18 
  
         45% 
 
   2. 
 
51-60 
 
                         22 
 
         55% 
 
 
                  
 
 
Inference: 
 
  According to the above mentioned data 45% of patients were 
in age groups 41-50 years, 55% of patients were in age group 51-60 years. 
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Thinai: 
 
 
Sl.No 
 
Thinai 
 
No.of patients/40 
 
     Percentage 
  1 Kurinji              0             0% 
  2 Mullai              0             0% 
  3 Marutham              16           40% 
  4 Neithal            24           60% 
  5 Paalai              0             0% 
 
 
                 
 
 
 
Inference 
  From the above data 60% of patient from neithal, 40% of 
cases from marutham. 
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Paruva kaalam : 
 
Sl.No 
 
Paruva Kaalam 
     
        Months 
 
No.of 
patients/40 
    
Percentage 
  1 Kaar kalam  Avani, Puratasi, 
Mid Aug-Mid 
Oct 
            10       25% 
  2 Koothir kalam Iyppasi, 
Kaarthigai 
Mid Oct-Mid 
Dec 
              6       15% 
  3 Munpani kalam Margazhi, Thai 
Mid Dec-Mid 
Feb 
              4         10% 
  4 Pinpani kalam Maasi, Panguni 
Mid Feb-Mid 
April 
              8         20% 
  5 Elavenil kalam Chithirai, 
vaigasi 
Mid April- Mid 
June 
              10       25% 
  6 Mudhuvenilkaalam Aani, Aadi 
Mid June-Mid 
Aug 
              2       5% 
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 Inference : 
   25% of case came in kaar kalam , 15% of case came in 
koothirkaalam , 10% of case came in munpanikalam , 20% of case came in 
pinpanikalam , 25% of case came in elavenil ,  and 5% of case in 
mudhuvenil kalam  
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Occupational Status: 
 
 
Sl.No 
 Occupational   
status 
 
No.of patients/40 
 
Percentage 
`  1 Drivers              4           10% 
   2 Labourers              10          25% 
   3 Professionals               6          15% 
   4 Businessman              8          20% 
   5  House wife              12          30% 
 
              
 
 
Inference 
10% of cases were drivers. 
25% of cases were  labourers. 
15% of cases were Business Man 
20% of cases were professional 
30% of cases were house wife 
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 Socio Economic Status:  
 
 
Sl.No 
Socio Economic 
Status 
 
No.of 
patients/40 
 
Percentage 
  1 Low income group 
(below 10000/month) 
            18       45% 
  2 Middle income group 
(10000 to 
20000/month) 
             14       35% 
  3 High income group 
(above 20000/month) 
             8       20% 
 
 
              
 
Inference 
  45% of cases belong to Low income group and 35% of 
patients belong to middle income group. 20% of cases belong to high 
income group. 
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Food Habits: 
 
 
Sl.No 
 
Food Habit 
 
No.of patients/40 
 
Percentage 
  1. Vegetarian Diet             10       25% 
  2. Mixed  Diet 
(including non 
veg) 
            30       75% 
 
 
                   
 
 
Inference 
 
75% of cases were mixed diet( Including non veg). 
25% of cases were Vegetarian. 
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Personal Habits: 
 
 
 
Sl.No 
  
Personal Habits 
 
No.of patients/40 
 
Percentage 
  1 Smoker               10         25% 
  2 Alcoholic               10         25% 
  3 Tobacco chewing               0           0% 
  4 Others               20         50% 
     
                
 
 
 
Inference 
  50% of patients had others, 25% of cases were smoker and 
25% of cases were alcoholic. 
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Symptoms: 
 
 
Sl.No 
 
Symptoms 
 
No.of patients/40 
 
Percentage 
  1 Acute pain in 
Shoulder Joints 
             40         100% 
  2 Tenderness,               10         25% 
  3 Stiffness               6         15% 
  4 Difficulty in moving 
the shoulder joints 
              6         15% 
  5 pain in the shoulder 
with radiation 
              4         10% 
 
            
        
      
Inference 
  100% of cases came with complaints of acute pain in the 
shoulder joints, and 25% of cases with tenderness, 15% of cases with 
stiffness and 15% of cases with difficulty in moving the shoulder joints , 
10% of cases with pain in the shoulder with radiation 
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Symptoms: 
 
 
Sl.No 
 
Sides of the joint 
affected 
 
No.of patients/40 
 
Percentage 
  1 Right side              24 60% 
  2 Left side             14 30% 
  3 Both               2 5% 
  
 
               
        
      
Inference 
  60% of cases came with complaints of acute pain in Rt side 
shoulder joint ,  30% of cases with  complaints of acute pain in left side 
shoulder joint  and  5% of cases with pain in the shoulder of both the sides. 
 
 
 
 
 
95 
 
 
Vatham: 
 
 
Sl.No 
 
Vatham 
 
No.of 
patients/40 
 
Percentage 
  1 Pranan              0             0% 
  2 Abanan             10            25% 
  3 Vyanan             40            100% 
  4 Udhanan   0             0% 
  5 Samanan              0             0% 
  6 Nagan              0             0% 
  7 Koorman              10             25% 
  8 Kirukaran              0             0% 
  9 Devathathan              0             0% 
 10 Dhananjeyan              0             0% 
 
                 
 
Inference 
Abaanan was affected in 25% of patients and Vyanan was affected in 
100% of patients, koorman was affected 25% of patients. 
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Pitham: 
 
 
Sl.No 
  
Pitham 
 
No.of patients/40 
 
Percentage 
  1 Anar Pitham             0          0% 
  2 Ranjaga Pitham             6          15% 
  3 Sadhaga Pitham            40          100% 
  4 Aalosaga 
Pitham 
           10          25% 
  5 Prasaga Pitham             0          0% 
 
                 
 
 
Inference 
Saathagam was affected in 100% of patients,  aalosagam was 
affected in 25% and ranjagapitham  was affected in 15 
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IYYAM: 
 
    
          
 
 
Inference 
 Tharpagam was affected in 25% of patients and Santhigam in 100% 
of patients. 
 
 
 
 
 
Sl.No 
  
Iyyam  
 
No.of patients/40 
 
Percentage 
   1 Avalambagam              0           0% 
   2 Kilethagam              0           0% 
   3 Bothagam              0           0% 
   4 Tharpagam              10          25% 
   5 Sandhigam              40          100% 
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Udal Kattugal: 
 
 
Sl.No 
  
Udal Kattugal 
 
No.of patients/40 
 
Percentage 
     1 Saaram                100             100% 
     2 Senner                6            15% 
     3 Oon                40            100% 
     4 Kozhuppu                40            100% 
     5 Enbu                40            100% 
     6 Moolai                0             0% 
     7 Sukkilam                0              0% 
 
                  
 
 
Inference 
 Saaram  was affected in 100% of patients , senner was affectrd in 
15% , Enbu was affected in 100% of patients , Oon affected in 100% 
,kozhuppu was affected in 100%. 
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Enn Vagai Thervu: 
 
 
Sl.No 
Enn Vagai 
Thervu 
 
No.of patients/40 
 
Percentage 
   1 Naa             6            15% 
   2 Niram             0            0% 
   3 Mozhi             0            0% 
   4 Vizhi            10            25% 
   5 Naadi            40            100% 
   6 Sparism             8            20% 
   7 Malam            10            25% 
   8 Moothiram             0            0% 
 
                
 
Inference 
 Naadi was affected in 100% of patients, malam was affected 25% , 
vizhi was affected 25% , sparism was affected in 20% , and 15% of 
patients naa  was affected . 
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Naadi: 
 
 
Sl.No 
 
          Naadi 
 
No.of patients/40 
 
Percentage 
   1 Vatham                16       40% 
   2 Vathapitham                24       60% 
 
 
                
 
 
Inference 
  In 40% of cases   vatha naadi was felt , and 60% of patient’s 
vatha pitham naadi was felt. 
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Neikkuri: 
 
 
Sl.No 
 
      Neikkuri 
 
No.of patients/40 
 
Percentage 
    1           Vali 
(spreads like 
snake) 
                
               30      
       
       75% 
    2          Azhal 
(spreads like ring) 
           
              10 
       
       25% 
    3          Iyyam 
(stands like pearl) 
                
               0 
        
        0% 
 
               
 
 
Inference: 
 70% of cases show vali neikuri and 25% shows azhal neikkuri. 
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Clinical Progress: 
 
Sl.No 
 
Symptoms 
No.of patients/40 Percentage 
     BT    AT    BT  AT 
  1 Acute pain in 
Shoulder Joints 
     40     6  100% 15% 
  2 Tenderness,       10     2    25%  5% 
  3 Stiffness,       6     2    15%  5% 
  4 Difficult in 
moving the 
shoulder joint. 
      6     2    15%  5% 
  5  Radiating pain       4     2   1 0%   5% 
 
           
 
Inference 
 Before treatment 100% of cases  Acute pain in Shoulder Joints, 
after treatment 15%  and before treatment  25% of cases Tenderness, 
after treatment  5% , before treatment 15% of cases stiffness after 
treatment 5% and before treatment 15% of cases difficulty in moving the 
shoulder joints after  treatment 5% , before treatment 10% radiating pain 
after treatment 5%. 
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Gradation of results: 
 
Sl.No 
 
Gradation of results 
 
No.of patients/40 
 
Percentage 
   1 Good Improvement                20        50% 
   2 Moderate 
Improvement 
               10        25% 
   3 Poor Improvement                10        25% 
 
                    
 
 
 
Inference ;  
50% of Patients show good improvement, 25% of shows moderate 
improvement and 25% of cases shows poor improvement. 
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LABORATORY INVESTIGATION REPORT ( OP ) 
 
  
 
TC – Total Count        Hb – Haemoglobin       OEC – Occasional Epithelial Cells 
Dc – Differential Count               ESR – Erythrocyte Sedimentation Rate     OPC – Occasional Pus Cells 
P – Polymorph        Alb – Albumin       FPC – Few Pus Cells 
L – Lymphocyte        Sug – Sugar        FEC – Few Epithelial Cells 
  E – Eosinophil        Dep – Deposits 
 
 
 
SL. 
NO. 
OP. NO.              
 
NAME 
 
AGE/SEX 
 
HEAMOTOLOGICAL REPORT 
URINE ANALYSIS STOOL  EXAMINATION 
BEFORE TREATMENT AFTER TREATMENT ESR(mm) HB(Gm) 
TC 
(Cu/mm
) 
DC 
TC 
(Cu/mm) 
DC BT AT 
BT AT 
BT AT BT AT 
P L E P L E ½ Hr 1 Hr ½ Hr 1 Hr Alb Sug Dep Alb Sug Dep Ova Cyst Ova Cyst 
1 174 Abdulkani 60/M 9700 59 37 4 9800 60 36 3 3 7 3 6 12 13.2 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
2 601 Arunagiri 52/M 9600 57 38 5 9600 60 37 4 3 5 3 8 12.8 13 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
3 3346 selvaraj 48/M 9400 56 34 6 9200 55 32 5 2 5 4 8 13.5 12.8 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
4 2559 gunasekaran 47/M 8700 54 42 4 9000 58 38 3 10 22 9 18 12.4 12.5 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
5 915 Ramasamy 50/M 10600 62 34 4 9800 57 30 4 7 17 8 16 12 13.1 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
6 891 Mahalaksmi 47/F 9800 56 39 5 9600 60 35 6 13 24 10 18 13 13.5 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
7 4727 Karpakam 59/F 9700 58 37 3 9700 55 35 3 10 18 15 20 12.5 12.1 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
8 7063 Mani 51/M 10700 66 30 4 10800 65 30 5 2 3 4 6 13 14.2 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
9 6391 Nagammal 52/F 9300 53 38 9 9400 55 35 6 14 20 9 16 13.8 13.7 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
10 4835 Subramani 55/M 9600 57 39 6 9500 56 35 4 6 14 3 9 14.8 15 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
11 4621 Anjalidevi 47/F 9700 57 38 5 9300 61 36 6 5 8 5 10 13.6 13.7 Nil Nil FPC Nil Nil FPC Nil Nil Nil Nil 
12 6850 Premkumar 60/M 10400 60 38 4 9900 58 40 5 15 25 8 18 14 13.5 Nil Nil FPC Nil Nil OPC Nil Nil Nil Nil 
13 312 Krishnamoorthy 60/M 9300 58 37 3 9600 60 36 3 11 23 10 15 12.4 13 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
14 4546 Kumar 57/M 9600 66 31 7 10500 60 34 8 15 30 12 18 15 14.5 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
15 2967 Natrajan 57/M 9800 55 42 3 9750 58 40 4 5 22 4 10 12.2 11.5 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
16 9781 Kumari 53/F 9400 56 33 2 9350 55 37 2 5 10 8 16 12.4 12.5 Nil Nil OEC Nil Nil Nil Nil Nil Nil Nil 
17 7895 Venkatesan 49/M 9000 55 39 3 9100 56 40 2 7 15 4 8 12 12.8 Nil Nil OEC Nil Nil Nil Nil Nil Nil Nil 
18 4508 Bahavathipillai 54/M 9300 59 37 4 9450 60 35 3 4 8 3 7 14.8 14.5 Nil Nil OEC Nil Nil Nil Nil Nil Nil Nil 
19 4795 Chelladurai 46/M 9400 57 33 7 9600 60 35 3 3 7 3 6 14.4 14.3 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
20 7445 Lakshmi 48/F 9200 56 35 6 9300 57 34 5 12 20 7 16 13.5 14 Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
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LABORATORY INVESTIGATION REPORT ( IP ) 
 
 
TC – Total Count        Hb – Haemoglobin       OEC – Occasional Epithelial Cells 
Dc – Differential Count               ESR – Erythrocyte Sedimentation Rate     OPC – Occasional Pus Cells 
P – Polymorph        Alb – Albumin       FPC – Few Pus Cells 
L – Lymphocyte        Sug – Sugar        FEC – Few Epithelial Cells 
  E – Eosinophil        Dep – Deposits 
 
 
 
 
 
SL. 
NO. 
OP. NO.              
 
NAME 
 
AGE 
 
HEAMOTOLOGICAL REPORT 
URINE ANALYSIS STOOL  EXAMINATION 
BEFORE TREATMENT AFTER TREATMENT ESR(mm) HB(Gm) 
TC 
(Cu/mm) 
DC 
TC 
(Cu/mm) 
DC BT AT 
BT AT 
BT AT BT AT 
P L E P L E ½ Hr 1 Hr ½ Hr 1 Hr Alb Sug Dep Alb Sug Dep Ova Cyst Ova Cyst 
1 244/1605 Selvaraj 52/M 9600 45 32 3 9700 52 36 3 2 5 3 6 14.1 14.2 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
2 260/2141 Vallayammal 45/F 9500 56 38 5 9600 59 37 4 3 5 3 7 12.8 13 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
3 95/8383 Anandhan 60/M 9400 58 34 6 9300 56 32 3 2 5 4 9 13 12.8 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
4 368/4493 Murugan 47/M 9400 58 39 3 9100 60 38 2 10 22 9 18 12.4 12.6 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
5 530/4159 Mahalakshmi 57/F 10600 60 34 4 10450 57 30 4 7 17 8 18 14 14.1 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
6 664/2789 Vennila 46/F 9400 56 39 5 9600 60 35 6 12 24 10 15 13 13.5 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
7 674/3076 Srinivasan 46/M 9700 58 37 2 9700 55 35 3 10 18 15 20 12.5 12.1 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
8 897/9214 Mani 60/M 10700 66 30 4 10800 65 30 5 2 3 4 6 14 14.2 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
9 921/9856 Rani 50/F 9300 57 38 3 9400 55 35 6 10 20 9 18 13.8 13.7 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
10 250/7524 Thulasi 45/F 9000 58 38 4 9200 53 35 4 2 4 3 6 14.8 14 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
11 267/7916 Yasodha 51/F 9000 60 32 8 8800 62 30 6 6 12 5 10 12.6 12.5 Nil Nil FPC Nil Nil FPC Nil Nil Nil Nil 
12 286/8306 Rakkaiyi 49/F 9700 54 42 4 9600 58 40 5 10 22 8 19 14 13.5 Nil Nil FPC Nil Nil OPC Nil Nil Nil Nil 
13 528/3082 Julli 60/F 10100 59 37 3 10300 60 36 3 15 25 10 13 13.2 13 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
14 534/3195 Thangamani 50/M 10700 62 31 7 10500 60 34 8 15 30 12 18 15 14.5 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
15 589/4272 Saroja 45/F 9800 55 42 3 9750 58 40 2 5 22 4 10 12.2 12.5 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
16 623/4995 Lakshmi 52/F 9300 56 38 6 9350 55 41 4 5 10 8 16 12.4 12.5 Nil Nil OEC Nil Nil Nil Nil Nil Nil Nil 
17 655/1367 Leenamery 56/F 9400 58 39 3 9450 56 40 2 3 5 4 8 12 12.2 Nil Nil OEC Nil Nil Nil Nil Nil Nil Nil 
18 849/3961 Durai 45/M 9600 59 37 4 9550 60 35 3 7 12 10 14 13 12.5 Nil Nil OEC Nil Nil Nil Nil Nil Nil Nil 
19 1309/3961 Kamachi 60/M 9600 58 36 6 9600 60 35 3 7 13 6 14 12.4 13 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
20 371/1502 Subramani 52/m 9000 59 35 6 9100 58 34 4 6 10 5 8 14.6 14 Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
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X-Ray Finding 
SL. NO. 
OP. NO/ IP NO. 
 
NAME 
 
AGE/SEX 
 
X-RAY INVESTIGATION 
1 174 Abdulkani 60/M Osteophytic changes + 
2 601 Arunagiri 52/M Normal 
3 3346 Selvaraj 48/M Normal 
4 2559 Gunasekaran 47/M Normal 
5 915 Ramasamy 50/M Normal 
6 891 Mahalaksmi 47/F Normal 
7 4727 Karpakam 59/F Osteophytic changes + 
8 7063 Mani 51/M Normal 
9 6391 Nagammal 52/F Normal 
10 4835 Subramani 55/M Normal 
11 4621 Anjalidevi 47/F Normal 
12 6850 Premkumar 60/M Osteophytic changes + 
13 312 Krishnamoorthy 60/M Osteophytic changes + 
14 4546 Kumar 57/M Normal 
15 2967 Natrajan 57/M Normal 
16 9781 Kumari 53/F Normal 
17 7895 Venkatesan 49/M Normal 
18 4508 Bahavathipillai 54/M Normal 
19 4795 Chelladurai 46/M Normal 
20 7445 Lakshmi 48/F Normal 
21 244/1605 Selvaraj 52/M Normal 
22 260/2141 Vallayammal 45/F Normal 
23 95/8383 Anandhan 60/M Osteophytic changes + 
24 368/4493 Murugan 47/M Normal 
25 530/4159 Mahalakshmi 57/F Osteophytic changes + 
26 664/2789 Vennila 46/F Normal 
27 674/3076 Srinivasan 46/M Normal 
28 897/9214 Mani 60/M Osteophytic changes + 
29 921/9856 Rani 50/F Normal 
30 250/7524 Thulasi 45/F Normal 
31 267/7916 Yasodha 51/F Normal 
32 286/8306 Rakkaiyi 49/F Normal 
33 528/3082 Julli 60/F Osteophytic changes + 
34 534/3195 Thangamani 50/M Normal 
35 589/4272 Saroja 45/F Normal 
36 623/4995 Lakshmi 52/F Normal 
37 655/1367 Leenamery 56/F Normal 
38 849/3961 Durai 45/M Normal 
39 1309/3961 Kamachi 60/M Osteophytic changes + 
40 371/1502 Subramani 52/m Normal 
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NORMAL X-RAY    RIGHT SHOULDER JOINT AP VIEW 
       
 
NORMAL X-RAY   LEFT SHOULDER JOINT AP VIEW 
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DISCUSSION 
 
Periarthritis of the shoulder joints is a chronic, retrograde and 
inflammatory disease of the shoulder joint, capsule and the soft tissues 
surrounding it. This pathology is mostly due to exposure to cold, trauma, or 
chronic strain of the shoulder. The main clinical manifestations are soreness 
and dysfunction of the shoulder. The disease is usually found in patients above 
the age of 50. 
In my study 40 patients were treated in outpatient and inpatient 
department of Post graduate pothumaruthuvam, Govt Siddha Medical College 
Hospital, Chennai – 106. 
All patients were subjected to preliminary investigations which include 
haematological, urine examination. Before Treatment purgative was given to 
all patients to balance the altered three doses. 
The Trial Medicine kanthagaparpam was administered from the next 
day onwards, course of Treatment is 20 days. 
Age Distribution: 
 According to the above mentioned data 45% of patients were in 
age groups 41-50 years, 55% of patients were in age group 51-60 years. 
. 
Distribution of Thinai:  
From the above data 60% of patient from neithal, 40% of cases from 
marutham. 
Paruvakalam: 
According to the above mentioned data .25% of case came in kaar 
kalam , 15% of case came in koothirkaalam , 10% of case came in 
munpanikalam , 20% of case came in pinpanikalam , 25% of case came in 
elavenil ,  and 5% of case in mudhuvenil kalam. 
Occupational Status: 
In my study 10% of cases were drivers. 
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25% of cases were  labourers. 
15% of cases were Business Man 
20% of cases were professional 
30% of cases were house wife. 
 
Socio Economic Status: 
According to this study , 45% of cases belong to Low income group and 
35% of patients belong to middle income group. 20% of cases belong to high 
income group. 
Food Habits: 
According to this study , 75% of cases were mixed diet(Including non 
veg), 25% of cases were Vegetarian. 
 
Personal Habits: 
In my study  50% of patients had other habits, 25% of cases were 
smoker and 25% of cases were alcoholic. 
Symptoms: 
            According to this study 100% of cases came with complaints of acute 
pain in the shoulder joints, and 25% of cases with tenderness, 15% of cases 
with stiffness and 15% of cases with difficulty in moving the shoulder joints , 
10% of cases with pain in the shoulder with radiation.  
 
 
Sides of the joints affected 
  60% of cases came with complaints of acute pain in Rt side 
shoulder joint ,  30% of cases with  complaints of acute pain in left side 
shoulder joint  and  5% of cases with pain in the shoulder of both the sides. 
Vali : 
 Abaanan was affected in 25% of patients and Vyanan was affected in 
100% of patients, koorman was affected 25% of patients. 
Azhal: 
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 Saathagam was affected in 100% of patients,  aalosagam was affected in 
25% and ranjagapitham  was affected in 15% . 
Iyyam: 
Tharpagam was affected in 25% of patients and Santhigam in 100% of 
patients. 
Udhal Kattugal: 
 Saaram  was affected in 100% of patients , senner was affectrd in 15% , 
Enbu was affected in 100% of patients , Oon affected in 100% ,kozhuppu was 
affected in 100%. 
Envagai Thervu: 
 Naadi was affected in 100% of patients, malam was affected 25% , vizhi 
was affected 25% , sparism was affected in 20% , and 15% of patients naa  was 
affected . 
Naadi: 
40% of patient’s vatha  naadi was felt and 60% of cases vatha pitha 
vatha naadi was felt.. 
Neikuri: 
70% of cases show vali neikuri and 25% shows azhal neikkuri. 
 
Clinical Progress: 
 Before treatment 100% of cases  Acute pain in Shoulder Joints, 
after treatment 15%  and before treatment  25% of cases Tenderness, after 
treatment 5% , before treatment 15% of cases stiffness after treatment 5% and 
before treatment 15% of cases difficulty in moving the shoulder joints after  
treatment 5% , before treatment 10% radiating pain after treatment 5%. 
 
. 
Trial Medicine: 
All the 40 patients treated with the Trial Medicine kanthaga parpam 
with honey for 20 days The disease and treatment are based primarily on the 
derangement of Mukkutram, which again is based on the Pancha bootham 
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theory.  Incidence of Kumba vatham and treatment are also based on these 
primary principles of Siddha medicine. 
 The bootham araises vatham kuttram in the body and so as leads 
to degenerate and weakness of shoulder joints. Increased vatha kuttram is 
brought to normal mainly by kaippu suvai and thuvarppu suvai. 
A.  Vinn + vayu = Kaippu 
B.  Earth+ vayu = Thuvarppu. Thus they decrease the vatha kuttram. 
So i conclude the trial drugs controls the disease Kumba vatham 
and it comes under the Ethirurai Maruthuvam 
 
Gradation of results: 
50% of Patients show good improvement, 25% of shows moderate 
improvement and 25% of cases shows poor improvement. 
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SUMMARY 
 
  The aim of the study is to reduce the symptoms of Periarthritis. . 
The trial medicine Kanthaga parpam was prepared as per literature. The 
duration of the trial period is 20 days. The trial dose is Kanthaga parpam 
200mg  ,twice a day with honey. I had selected 40 patients for the trial based on 
Inclusion and Exclusion criteria. Before treatment routine blood, urine analysis 
taken in all 40 patients. Siddha methods like udal thathukkal, Envagai thervu, 
Neerkuri and Neikuri were noted in case sheet proforma. Patients were 
instructed to come for next review once in 7 days. The entire details of the 
patients were noted in the case sheet proforma. 
 
Age : 
  Most of the patients were in the age group between 51-60 years. 
 
Thinai : 
  Most of the patients were from Neithal Thinai 60%. 
 
Kalam : 
  Seasonal Variances do not have any impact for affecting the 
people. 
 
Occupation: 
  The disease is more common in people working  as Labourers & 
housewifes. 
 
Diet & Personal habits: 
  People with habit of taking Vegetarian and Mixed Diet(Including 
non veg), smoking, Alcoholic have more incidence of the disease. 
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Mukkutram: 
  In Vali, abaanan, koorman and viyanan, in Azhal Sathagam & 
Aalosagam  and in Iyyam Santhiagam were affected in most of the cases. 
 
Udal Thathugal: 
  Saaram, Oon, Kozhuppu, Enbu  were affected in all the patients. 
 
Naadi : 
  Vathapitha  naadi was most common naadi felt. 
 
Results after treatment: 
 
  50% of patients show good improvement, 25% of patients shows 
moderate improvement and in 25% of patients poor improvement was 
observed. 
. 
  The pharmacological studies reveal that trial drugs had good 
Anti-arthritis effect in rats. The toxicity study revealed that there were no signs 
of toxicity as could be judged by the absence of undesirable clinical 
manifestations and no alteration in bio chemical markers. 
 
  The bio-statistical report of the clinical trial shows significant 
result. 
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CONCLUSION 
 
 
 KUMBAVATHAM  (Periarthritis) is primarly due to the derangement  
of vatham  
 The trial medicine Kanthaga parpam  predominating with  kaippu taste 
respectively neutralizes the vatham . 
 From the pre clinical pharmacological studies it is evident that the 
medicines were significant Anti-arthritis  activity. 
 The Kanthaga parpam  do not produce any toxicity in preclinical study. 
So it is non toxic and safe drug for Kumba vatham. 
 In Bio-chemical analysis the trial medicine contains zinc and 
calcium,magnesium . These are very essential for  strengthening the 
joints. 
 No contra indication was reported during the course of the treatment. 
 The trial medicines gave maximam relief from the symptoms of Kumba 
vatham. 
 The prepration of trial medicines is easy and economical. 
 Therefore the author concluded that the trial medicine KANTHAGA 
PARPAM should be a very positive remedy for Kumba vatham( 
Periarthritis). 
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Bio-Chemical 
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BIOCHEMICAL ANALYSIS OF TRIAL MEDICINES 
 
Preparation of Sodium Carbonate extract: 2 gm of the sample drug  is 
mixed  5 gm of Sodium carbonate and taken in a 100 ml beaker and 20 ml of 
distilled water is added.  The solution is boiled for 10 minutes, cooled and then 
filtered.  The filtrate is called sodium carbonate extract. 
 
S.No. 
 
Experiment 
 
Observation  
 
Inference 
1 Test for Acid Radicals   
a. Test for Sulphate 
2 ml of the above prepared extract 
is taken in a test tube.  To this add 
2ml of 4% Ammonium oxalate 
solution. 
Absence of              
White  Precipitate 
 
Absent 
b. 2ml of extract is added with 2ml 
of dilute hydrochloric acid until 
the effervescence ceases off.  Then 
2ml barium chloride solution is 
added. 
Absence of              
White  Precipitate 
 
Absent 
2. Test for Chloride: 
2ml of extract is added with dilute 
nitric acid till the effervescence 
ceases.  Then 2ml of silver nitrate 
solution is added. 
 
 Absence of white 
precipitate. 
 
Absent 
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3. Test for Phosphate 
2ml of the extract is treated 
with 2 ml of Ammonium 
molybdate  solution and 2ml of 
concentrated nitric acid. 
Absence of 
Yellow Precipitate 
 
Absent 
4. Test for Carbonate: 
2ml of the extract is treated 
with 2ml of magnesium 
sulphate solution. 
Absence of white 
precipitate 
 
Absent 
5. Test for Sulphide: 
1 gm of the substance is treated 
with 2ml of concentrated 
Hydrochloric acid 
Absence of Rotten 
egg smelling 
 
             Absent 
6. Test for Nitrate: 
1gm of the substance is heated 
with copper turnings and 
concentrated sulphuric acid 
and viewed the test tube 
vertically down. 
Absence of reddish 
brown gas. 
      
            Absent 
7. 
a. 
Test for Fluoride and oxalate 
2ml of the extract is added with 
2ml of dilute acetic acid and 
2ml of calcium chloride 
solution and heated.  
Absence of white 
precipitate 
       
            Absent 
b. 5 drops of clear solution is 
added with 2ml of dilute 
sulphuric acid and slightly 
warmed to this, 1 ml of dilute 
potassium permanganate 
solution is added.  
Absence of KMNO4 
solution 
discolourisation.  
          
            Absent 
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8. Test for Nitrite 
3 drops of the extract is placed 
on a filter paper.  On that, 2 
drops a Acetic Acid and 2 
drops of Benzidine solution is 
placed. 
Absence of 
yellowish red colour 
 
           Absent 
9. Test for Borate 
2 pinches of the substance is 
made into paste by using 
Sulphuric acid and Alcohol 
(95%) and introduced into the 
blue flame. 
Absence of Green 
tinged flame 
 
            Absent  
II. TEST FOR BASIC RADICALS  
10. Test for lead 
2 ml of the extract is added 
with 2 ml of Potassium iodide 
solution 
Absence of Yellow 
precipitate 
 
             Absent 
11a Test for Copper 
One pinch of substance is 
made into paste with 
concentrated Hydrochloric acid 
in a watch glass and introduced 
into the non luminous part of 
the flame. 
Absence of Bluish 
green coloured 
flame. 
 
             Absent 
b. 2ml of the extract is added with 
excess of Ammonia solution 
Absence of deep 
blue 
                 
            Absent 
12. Test for Aluminium 
To the 2 ml of extract.  Sodium 
Hydroxide solution is added in 
drops to excess. 
Absence of   White 
precipitate. 
 
            Absent  
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13a Test for Iron 
To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
solution is added. 
Absence of Blood 
red colour 
 
Absent 
b. To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
solution and 2 ml of 
concentrated Nitric Acid is 
added. 
Absence of Blood 
red colour. 
 
Absent 
14. Test for Zinc 
To the 2 ml of extract Sodium 
Hydroxide solution is added in 
drops to excess. 
  White precipitate  
Obtained 
 
Present 
 15. Test for Calcium 
2 ml of the extract is added 
with 2 ml of 4% Ammonium 
Oxalate solution. 
White precipitate 
Obtained 
 
Present 
16. Test for Magnesium 
 2ml of extract, Sodium 
Hydroxide solution is added in 
drops to excess. 
  White precipitate 
Obtained 
 
Present 
17. Test for Ammonium 
 2 ml of extract few ml of 
Nessler’s Reagent and excess 
of Sodium Hydroxide solution 
are added. 
 
Absence of   
Reddish brown 
precipitate . 
 
Absent 
18. Test for Potassium 
A pinch of substance is treated 
with 2 ml of Sodium Nitrite 
Absence of Yellow 
precipitate. 
Absent 
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solution and then treated with 2 
ml of Cobal Nitrate in 30% 
glacial Acetic acid. 
19. Test for Sodium 
2 pinches of the substance is 
made into paste by using 
Hydrochloric acid and 
introduced into the blue flame. 
Absence of Yellow 
colour flame 
 
Absent 
20. Test for Mercury 
2 ml of the extract is treated 
with 2 ml of Sodium 
Hydroxide solution. 
Absence of yellow 
precipitate 
 
Absent 
21. Test for Arsenic 
2 ml of extract is treated with 2 
ml of silver Nitrate solution 
Absence of                                                                                                                    
Yellow precipitate. 
 
Absent 
22. Test for Starch 
2ml of extract is treated with 
weak iodine solution 
Absence of 
Bluecolour  
 
Absent 
23. Test of reducing Sugar 
5ml of Benedicts qualitative 
solution is taken in a test tube 
and allowed to boil for 2 
minutes and added  10 drops of 
the extract and again boiled for 
2 minutes.  The colour changes 
are noted. 
Absence of Green 
colour  
 
Absent 
24.  Test of  the alkaliods               
2ml of the extract is treated 
with  2ml of potassium lodide 
solution. 
Absence of Red 
colour  
Absent 
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25. 
 
 
 
 
Test of  the proteins 
2ml of the extract is treated 
with  2ml of 5% NaOH ,mix 
well and add 2 drops of copper 
sulphate solution. 
Absence of Violet  
colour  
Absent 
 
 
 
RESULTS:   
 
The given sample contains. 
Drug  Name (Kanthaga parpam) –  
a. Zinc 
b. Calcium 
c. Megnesium 
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ACUTE AND SUB ACUTE TOXICITY STUDY ON KANTHAGA 
PARPAM  
Animals  
 Mice of either sex weighing 25-30g and rats weighing 210-240g were 
obtained from the animal house of Vels University. The animals were used 
with the approval of the Institute animal ethics committee and obtained from 
Vels University, Chennai. They were fed with a balanced standard pellet diet 
and maintained under standard laboratory conditions, providing 24-
280Ctemperature, standard light cycle (12 h light, 12 h dark) and water ad 
libitum. Animals were kept in cages with raised floors of wide mesh to prevent 
coprophagy. Animal welfare guidelines were observed during the maintenance 
period and experimentation. The rats were randomly assigned to control and 
different treatment groups, six animals per group. The animals were 
acclimatized for one week under laboratory conditions.  
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the KanthagaParpam was carried out as per 
OECD Guidelines 425. As with other sequential test designs, care was taken to 
ensure that animals are available in the appropriate size and age range for the 
entire study. The test substance is administered in a single dose by gavage 
using a stomach tube or a suitable intubation cannula. The fasted body weight 
of each animal is determined and the dose is calculated according to the body 
weight. After the substance has been administered, food was withheld for a 
further 2 hours in mice. The animals were observed continuously for the first 4 
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h and then each hour for the next 24 h and at 6 hourly intervals for the 
following 48 h after administering of the test drug, to observe any death or 
changes in general behaviour and other physiological activities. Single animals 
are dosed in sequence usually at 48 h intervals. However, the time interval 
between dosing is determined by the onset, duration, and severity of toxic 
signs. Treatment of an animal at the next dose was delayed until one is 
confident of survival of the previously dosed animal.  
Observation of toxicity signs: General behavior, respiratory pattern, 
cardiovascular signs, motor activities, reflexes, change in skin and fur, 
mortality and the body weight changes were monitored daily. The time of 
onset, intensity, and duration of these signs, if any, was recorded.  
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, 24 either sex rats were divided 
into four groups of 6 rats each. Group I that served as normal control was 
administered with distilled water (p.o.) while groups II, III and IV were 
administered daily with the Kanthaga Parpam (p.o.) for 28 days at a dose of 
12.5, 25 and 50mg/kg respectively. The animals were then observed daily for 
gross behavioural changes and any other signs of subacute toxicity. The weight 
of each rat was recorded on day 0 and weekly throughout the course of the 
study, food and water consumption per rat was calculated. At the end of the 28 
days they were fasted overnight, each animal was anaesthetized with 
diethylether, following which they were then dissected and blood samples were 
obtained by cardiac puncture into heparinised tubes. The blood sample 
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collected from each rat was centrifuged with 3000 X g at 4oC for 10 min to 
separate the serum and used for the biochemical assays.  
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18 h and 
then anesthetized with anesthetic ether on the 28th day. Blood samples for 
hematological and blood chemical analyses were taken from retro orbital vein. 
Heparinized blood samples were taken for determining complete blood count 
(white blood cell count, differential white blood cell count, platelet count, red 
blood cell count, hematocrit, and hemoglobin) by semiautomated hematology 
analyzer. The serum from non-heparinized blood was carefully collected for 
blood chemistry and enzyme analysis (glucose, creatinine, total protein, 
albumin, total and direct bilirubins, serum glutamate-oxaloacetate transaminase 
(SGOT), serum glutamate pyruvate transaminase (SGPT), and alkaline 
phosphatase (ALP)) were automatically determined using autoanalyzer. 
Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, 
sizes and colors of internal organs were evaluated. The Spleen, Testes, Pancrea, 
Lung, Liver, Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues 
were excised from all rats to visually detect gross lesions, and weighed to 
determine relative organs’ weights and preserved in 10% neutral formalin for 
histopathological assessment. The tissues were embedded in paraffin, and then 
sectioned, stained with haematoxylin and eosin and were examined 
microscopically. 
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Statistical analysis 
 Values were represented as mean ± SEM. Data were analysed using 
one-way analysis of variance (ANOVA) and group means were compared 
using the Tukey-Kramer Multiple Comparison test using GraphPad Instat-V3 
software. P < 0.05 were considered significant. 
RESULTS 
 Animals treated with Kanthaga Parpam above 25mg/kg were shown 
significant toxic clinical signs during the dosing period of 28 days. All animals 
from control and all the treated dose groups not survived throughout the dosing 
period of 28 days and it was found two animal dead after 20days of treatment 
in moderate and high dose. Results of body weight determination of animals of 
control and different dose groups exhibited body weight loss throughout the 
dosing period of 28 days. During dosing period, the quantity of food consumed 
by animals from different dose groups was found to be comparable and normal 
with that of control animals.  
 Ophthalmoscopic examination of animals in control and Kanthaga 
Parpam treated group revealed remarkable abnormality in liver and kidney. 
Urine analysis data of control group and treated group of animals determined in 
week 4 did not reveal any significant abnormalities except pH changes. 
Comparison of organ weights of treated animals with respective control 
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animals on day 28 was found to be altered. Gross pathological examination of 
animals in the Kanthaga Parpam treated group revealed abnormalities.  
 The results of haematological investigations conducted on day 28, 
revealed changes in the values of different parameters investigated when 
compared with those of respective controls; Results of Biochemical 
investigations revealed the few significant changes in the values of different 
parameters studied when compared with those of respective controls; however, 
the values obtained were within biological and laboratory limits.  
CONCLUSION 
 In the present toxicological investigation, toxic effect was observed at 
both 25 and 50mg/kg of Kanthaga Parpam treated via oral route over a period 
of 28 days. So, it can be concluded that the Kanthaga Parpam can be prescribed 
for therapeutic use in human with the dosage minimization of upto 12.5mg/kg. 
body weight p.o. and also recommended for necessary close monitoring of 
signs of toxicity. 
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1. Table 1: Dose finding experiment and its behavioral Signs of Toxicity 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
 
250 + - - + - + - - - - - - - - - - - - - - 
 
500 + + - + - + - + - - - - - - + - - + + + 
 
1000 + + - + - + - + + + - - - + + + + + + + 
 
2000 + + - + - + - + + + - - - + + + + + + + 
2. 1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor Activity 8. Tremors 9. Convulsions 10. 
Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. 
Mortality 
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3. Table 2. Body wt (g) of rats exposed to Kandhaga Parpam for 28days. 
Dose (mg/kg/day) Days 
1 7 14 21 28 
Control 120.10±5.34 125.52±5.05 128.10±4.18* 132.54±4.64* 135.19±5.00** 
12.5 125.88±4.24 128.21±4.15 127.37±5.11 130.33±4.15 130.20±5.14 
25 128.21±5.52 125.12±4.91 122.15±5.02 120.00±5.11* 120.42±5.01* 
50 130.34±4.11 125.10±5.84 124.25±4.62* 125.18±5.14* 121.20±4.20** 
4. Values are mean ± S.E.M. (Dunnet ’t' test). *P>0.05. N=6. 
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5. Table 3. Food intake of rats exposed to Kandhaga Parpam for 28days. 
Dose (mg/kg/day) Days (gms/rats) 
1 7 14 21 28 
Control 45.28±2.25 45.14±2.28 45.25±2.25 46.12±2.24 47.17±2.12 
12.5 44.41±2.50 46.42±2.51 44.30±2.53 45.00±2.18 44.16±3.11 
25 46.24±2.34 45.10±2.38 45.23±2.42 45.51±2.10 45.14±2.10 
50 45.12±2.72 45.55±2.26 44.48±2.84 45.30±2.44 45.28±2.15 
6. Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05. N=6. 
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7. Table 4. Water intake of rats exposed to Kandhaga Parpam for 28days. 
 
Dose (mg/kg/day) 
Days(ml/rat) 
1 7 14 21 28 
Control 46.14±2.53 50.12±2.24 50.22±3.15 51.21±2.18 50.12±3.12 
12.5 45.10±2.20 45.15±2.17 51.12±3.22 44.42±2.80 49.27±2.24 
25 48.52±2.32 45.42±3.04 45.00±2.00 45.12±2.51 45.42±3.04 
50 50.18±2.55 50.55±2.10 50.41±2.12 48.18±2.15 45.45±2.42 
8. Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.05.. N=6. 
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9. Table 5. Hematological parameters after 28days treatment with Kandhaga Parpam. 
Parameter Control 12.5mg/kg 25mg/kg 50mg/kg 
Red blood cell (mm3) 5.10±0.42 5.00±0.36 4.18±0.29** 4.32±0.44* 
HB (%) 17.27±0.32 15.12±0.22 14.56±0.30** 14.01±0.28** 
Leukocyte (x103/Cu.mm) 8.88±1.2 8.12±0.71 7.05±0.92 6.79±1.05* 
Platelets(K/µl) 454±12.14 480±20.21 475±23.12 448±22.11 
MCV (gl) 52.10±4.00 54.05±4.82 54.12±4.65 54.80±4.51 
Neutrophil 15.28±1.15 15.12±0.90 15.51±0.84 15.12±3.24 
Lymphocyte 82.10±2.12 80.18±2.75 88.14±3.36 89.10±3.78 
Monocyte 1.48±0.30 1.51±0.32 1.39±0.30 1.42±0.22 
Eosinophil 1.00±0.14 1.00±0.20 1.00±0.12 1.00±0.10 
Basophil 0±0.00 1±0.00 0±0.00 1±0.00 
ESR(mm) 1±00 4±0.02** 6±0.04** 7±0.05** 
PCV 57.18±2.51 54.52±2.92 55.48±3.22 56.42±3.14 
10. Values are mean ± S.E.M. (Dunnet ’t' test). **P<0.01. N=6. 
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11. Table 6. Effect of treatment with Kandhaga Parpam biochemical parameters 
Dose (mg/kg) Control 12.5mg/kg 25mg/kg 50mg/kg 
Total Bilirubin (mg/dL) 0.30±0.05 0.32±0.04 0.33±0.05 0.35±0.06* 
Bilirubin direct (mg/dL) 0.24±0.03 0.28±0.05 0.28±0.05 0.31±0.04* 
ALP (U/L) 102.20±4.12 105.14±6.00 107.55±5.24 109.25±5.15** 
SGOT (U/L) 110.18±4.33 112.54±4.41 117.20±5.12 112.22±5.44 
SGPT(U/L) 35.24±2.84 34.55±2.20 34.51±2.18 36.56±2.25 
Total Protein(g/dl) 6.22±1.52 6.10±1.14 6.12±0.92 8.12±0.70 
Albumin(g/dl) 2.10±0.20 2.17±0.27 3.28±0.32* 3.14±0.14 
Globulin(g/dl) 4.88±0.17 5.00±0.22 5.10±0.24* 4.98±0.21 
12. Values are mean ± S.E.M. (Dunnet ’t' test). *P<0.05; **P<0.01 Vs Control N=6. 
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13. Table-7 RFT 
Dose (mg/kg) Control 12.5mg/kg 25mg/kg 50mg/kg 
Urea (mg/dL) 4.48±1.56 4.90±2.28 5.65±2.00 6.88±1.10** 
Creatinine (mg/dL) 0.70±0.04 0.72±0.05 0.74±0.05* 0.78±0.04** 
Uric acid (mg/dL) 3.58±0.12 4.35±0.10 4.69±0.14** 5.05±0.10* 
Na m.mol 112.42±5.11 118.20±4.20 116.42±5.42 121.10±3.68** 
K m.mol 6.10±2.51 6.00±1.14 6.25±1.35 6.14±2.42 
Cl m.mol 102.4±4.12 105.28±5.10 105.20±4.55 104.65±5.21 
14. Values are mean ± S.E.M. *P<0.05; **P<0.01. Vs. Control N=6 
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15. Table-8. Lipid Profile 
Dose (mg/kg) Control 12.5mg/kg 25mg/kg 50mg/kg 
Total cholestrol(mg/dL) 72.18±2.24 72.45±2.12 74.05±3.22 73.24±2.17 
HDL(mg/dL) 125.22±2.48 125.24±2.80 126.42±3.72 125.14±2.99 
LDL(mg/dL) 41.40±2.54 41.55±2.18 42.72±2.83 42.11±3.12 
VLDL(mg/dl) 25.72±2.48 25.64±2.34 26.00±2.56 26.10±2.24 
Triglycerides (mg/dl) 26.51±3.12 25.50±2.28 25.44±2.11 25.42±2.71 
Blood glucose(mg/dl) 92.00±4.00 91.12±4.42 92.10±4.24 92.20±2.65 
16. Values are mean ± S.E.M. (Dunnet ’t' test). nsP>0.01 Vs Control N=6. 
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17. Table-9 Urine Analysis 
Parameters Control 12.5mg/kg 25mg/kg 50mg/kg 
Colour Yellow Yellow Dark Brown Reddish Yellow 
Transparency Clear Slightly turbid cloudy Turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >8.2 >8.4 
Protein Nil 1+ 1+ 2+ 
Glucose Nil Nil Nil Trace 
Bilirubin -ve -ve -ve -ve 
Ketones -ve -ve +ve +ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Normal Normal Normal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen Bacteria seen 
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18. Table 10. Effect of Kandhaga Parpam on organ weight 
Dose (mg/kg) Control 12.5mg/kg 25mg/kg 50mg/kg 
Liver (g) 3.12±0.12 3.12±0.10 3.00±0.12 2.88±0.14* 
Heart (g) 0.30±0.04 0.30±0.03 0.31±0.02 0.31±0.04 
Lung (g) 0.45±0.10 0.44±0.11 0.45±0.12 0.44±0.15 
Spleen (g) 0.45±0.04 0.45±0.04 0.45±0.05 0.46±0.04 
Ovary (g) 1.71±0.26 1.65±0.22 1.71±0.22 1.67±0.25 
Testes (g) 2.12±0.10 2.41±0.12 2.32±0.14 2.42±0.16 
Brain (g) 1.20±0.16 2.12±0.10 2.15±0.12 2.12±0.15 
Kidney (g) 0.80±0.05 0.80±0.06 0.78±0.04* 0.75±0.04* 
Stomach (g) 1.10±0.10 1.12±0.10 1.14±0.11 1.13±0.13 
19. Values are mean ± S.E.M. (Dunnet ’t' test). *P<0.05 Vs Control N=6. 
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HISTOPATHOLOGY OF KANTHAGA PARPAM 
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ANTIARTHRITIC ACTIVITY OF KANTHAGA PARPAM IN 
COMPLETE FREUND’S ADJUVANT INDUCED ARTHRITIC RATS 
INTRODUCTION 
 Every day antiarthritic drugs are taken by more than 30 million people 
worldwide; of these, 40% of consumers are older than 60. Population studies 
have shown that 10–20% of all people who are 65 years or older either are 
currently receiving or have recently received a prescription for nonsteroidal 
antirheumatic drugs. During the next 20 years the number of people over 65 is 
expected to increase from 380 million to 600 million.  
 The very frequent use of NSAIDs is based on the fact that these agents 
have many indications for which a large number of patients exist. These 
indications include chronic polyarthritis, psoriatic arthritis, ankylosing 
spondylitis, osteoarthritis, gout, inflammatory soft tissue rheumatism, low back 
pain, postoperative and post-traumatic inflammation, thrombophlebitis and 
vasculitis. Over the past 140 years chemical substances have been introduced 
for therapy, collectively termed nonsteroidal anti-inflammatory drugs. Cyclo-
oxygenase, also known as prostaglandin H synthase, catalyzes the conversion 
of arachidonic acid to the prostaglandin endoperoxides PGG 2 and PGH 2, with 
the addition of two oxygen molecules. In this pathway two reaction steps can 
be differentiated, catalyzed by different domains of the cyclo-oxygenase 
protein. The first is the cyclo-oxygenase reaction, and the second is the 
peroxidase reaction.  
 Prostaglandins are formed in numerous types of cell within an organism. 
Their effects are complex and depend on the type of target cells, among other 
factors. For this reason it is difficult  
to generalize the physiological roles of individual prostaglandins, because the 
same compound can some-times exert even opposite effects on different types 
of target cell. Prostaglandins are important in the regulation of thrombocyte 
aggregation, inflammatory processes, pain and fever induction, the regulation 
of vessel perfusion, and many other processes.  
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 From these properties one can deduce the spectrum of activity of 
prostaglandin biosynthesis inhibitors such as indomethacin, ibuprofen and 
acetyl salicylic acid: NSAIDs function as anti-inflammatory, antipyretic and 
analgesic substances. NSAIDs that are not COX-2 selective produce GI side 
effects in between 20% and 40% of all individuals who take them. The extent 
of this disease, known as NSAID-gastropathy, varies considerably from 
asymptomatic mucosal damage that is detectable only with an endoscope, 
through gastric pain, heartburn and dyspepsia, to life-threatening, bleeding, 
gastric or duodenal ulcers.  
 Older women are more predisposed than older men towards developing 
an NSAID-induced ulcer, in which the stomach is more often involved than the 
duodenum. In more than 10–20% of patients, the first manifestation of an 
NSAID gastropathy can be a severe GI complication. Various studies have 
identified the following risk factors for NSAID-induced GI side effects that can 
in part be brought into the planning of prophylaxis: simultaneous corticosteroid 
therapy, earlier GI side effects, high dosage and long duration of NSAID 
therapy, advanced patient age, alcoholism, handicaps, and simultaneous 
anticoagulant therapy. When these risk factors are present, the indication for 
NSAID therapy must be thoroughly scrutinized.  
 Arthritis means an inflamed joint.  A joint normally consists of two 
cartilage-covered bone surfaces that glide smoothly against one another.  When 
joints become inflamed, the joint swells and does not move smoothly.  Over 
time, the gliding surface wears out.  There are many types of arthritis.  
Rheumatoid arthritis is just one type.  Wear and tear arthritis (osteoarthritis), 
gouty arthritis, and psoriatic arthritis are three other common types.   
Rheumatoid Arthritis is considered a systemic disease.  That is, it can affect 
many parts of the body.  Patients often awaken with stiff and swollen 
joints.  Early on, many patients feel tired.   Two thirds of patients with 
rheumatoid arthritis have wrist and hand problems. 
 Rheumatoid arthritis affects the cells that lubricate and line joints.  This 
tissue – synovium- becomes inflamed and swollen.  The swollen tissues stretch 
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supporting structures of the joints such as ligaments and tendons.  As the 
support structures stretch out, the joints become deformed and unstable.  The 
joint cartilage and bone erode.  Often the joints feel hot and look 
red.  Rheumatoid arthritis of the hand is most common in the wrist and 
knuckles.  The disease is symmetric, thus what occurs in one hand usually 
occurs in the other.    
Signs and symptoms of rheumatoid arthritis  
While stiffness, swelling, and pain are symptoms common to all forms of 
arthritis, there are some symptoms that are classic features of rheumatoid 
arthritis.  They are: Firm nodules along fingers or the elbow, Soft lump on the 
back of the hand that moves as the fingers straighten, Angulation  or collapse 
of fingers, Sudden inability to straighten or bend a finger because of a tendon 
rupture, Deformity in which the middle finger joint becomes bent, Deformity  
where the end of the finger is bent and the middle joint over extends, 
Prominent bones in the wrist. In addition, patients with rheumatoid arthritis 
often have problems with numbness and tingling in their hand (carpal tunnel 
syndrome) because the swelling of the tendons causes pressure on the adjacent 
nerve.  They may make a squeaky sound as they move joints (crepitus) and 
sometimes the joints snap or lock because of the swelling.   
 The current treatment of rheumatoid arthritis is intended to minimize the 
associated pain and inflammation using non-steroidal anti-inflammatory drugs 
as well as to decelerate the progress of the disease by using disease-modifying 
anti-rheumatic drugs. NSAIDs may be more effective in the treatment of 
rheumatoid arthritis, but there is a scarcity of such drugs acting through 
multiple mechanisms.  
 Hence, the treatment of rheumatoid arthritis involves the combined use 
of NSAIDs and disease modifying anti-rheumatic drugs. Due to chronic nature 
of rheumatoid arthritis, advanced age of the patients and adverse reactions of 
the NSAIDs and disease-modifying anti-rheumatic drugs, the arthritic patients 
tend to search for alternative treatments that are effective and less toxic and 
reduce the pill burden. Hence, they commonly prefer complementary and 
141 
 
alternative medicines. Hence, in the present work was designed to evaluate the 
safety and antiarthritic potential of traditionally used Kanthaga parpam in 
siddha system of medicine in a scientific manner. 
MATERIALS AND METHODS 
Drugs, Chemicals and Preparation of stock Solution 
 Diclofenac sodium and Carboxy methyl Cellulose were obtained from 
Sigma Aldrich, USA. Incomplete Freund’s adjuvant and Mycobacterium 
tuberculosis H37RA was obtained from DIFFCO Laboratories. CFA emulsified 
solution was prepared by triturating 1 mg of non viable, desiccated 
Mycobacterium tuberculosis in 1 ml of Fruend’s adjuvant. Diclofenac was 
prepared by dissolving in water for injection. Kanthaga Parpam was dissolved 
in 2% of CMC and made into suspension form. 
Animals  
 Wistar rats of either sex (100–150 g weight) were used in this study. 
The animals were maintained in plastic cages at 22 ± 2°C with free access to 
pellet food and water. The experimental protocols were approved by the 
Institutional Animal Ethical Committee (Approval. No. 
XIII/VELS/PCOL/07/2000/CPCSEA/IAEC/08.08.2012)constituted as per the 
rules of the Committee for the Purpose of Control and Supervision of 
Experiments on Animals. 
CFA-Induced Arthritis in Rats 
 Each treatment group contained six Wistar rats. The rats were randomly 
divided into four groups: CFA control, Kanthaga Parpam 
(25 mg  kg −1 day −1, p.o.), Kanthaga Parpam (50 mg  kg −1 day −1, p.o.), 
and Diclofenac sodium (45 mg  kg −1 day −1, p.o.). On day 0, arthritis was 
induced by injection of 100  μL CFA, containing heat-killed and 
dried Mycobacterium tuberculosis into the paw of the right hind limb of each 
rat. The Severity of Arthritis was evaluated with the consideration of the 
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primary and secondary lesions, that is, paw volumes of injected and non-
injected paws, were measured using a plethysmometer, after which adjuvant 
was administered. The lesions were measured again on the 7th, 14th, and 21st 
days after injection of the adjuvant.  
 During the experimental period, the body weight was measured using a 
digital weighing balance every 3rd day after adjuvant injection. The severity of 
arthritis was recorded by a blinded observer using the visual arthritis scoring 
systems. The arthritis score ranged from 0 to 4; where 0 indicates the least but 
definite swelling and 4 represents the maximum swelling. This scoring system 
involves observations of all four paws and giving a separate score for each 
limb. Scores were assigned (Data not shown) for evaluation of the pain 
associated with the arthritis.  
 Apart from this, the haematological parameters were evaluated using 
routine laboratory methods. The level of serum CRP and RF was determined 
using commercial kits. Similarly, On day 21, animals were anesthetized with 
anesthetic ether. The severity of the swelling of the soft tissue around the joints 
of the hind paws, periarticular bone resorption, periarticular bone erosion and 
narrowing of the joint space were evaluated.  
Statistical Analysis 
 The results are expressed as the mean ± SEM. The significance of the 
difference was evaluated by one-way ANOVA followed by Dunnet's multiple 
comparisons test. Data were considered statistically significant if P<0.05. 
RESULTS 
 Observations such as the paw volumes, body weight, hematological and 
biochemical parameters were recorded on the 7th, 14th, and 21st days after 
adjuvant injection. The CFA-induced arthritis control group showed signs of 
arthritis development, as seen by the increase in the paw volumes in both CFA-
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injected and CFA-non-injected paws, which indicates primary and secondary 
arthritic lesions. Other indications, such as a decreased body weight and 
alterations in the arthritis scores, also showed induction of arthritis in the CFA-
treated control group rats. 
 The assessment made on the 21st day showed that the standard drug 
Diclofenac sodium and Kanthaga Parpam treatments had significantly reduced 
the adjuvant-induced primary and secondary lesions in the respective treatment 
groups as compared with the CFA control group. It is noteworthy that the 
reduction in the secondary lesions was comparable in the Diclofenac sodium-
treated and Kanthaga Parpam50 mg/kg treated groups. The average gain in the 
body weight on day 21 was compared with the initial body weight in each 
treatment group. The rats in the CFA control group gained less body weight 
and statistically not significant as compared with the Kanthaga Parpam and 
Diclofenac sodium-treated groups. This effect on the body weight was clearly 
evident even at the lowest tested dose of 25 mg/kg of Kanthaga Parpam.  
 The CFA-induced haematological perturbations, such as an increase in 
the WBC count, a decreased RBC count, a decreased hemoglobin count and an 
increased erythrocyte sedimentation rate were also observed in Kanthaga 
Parpam treatment group of animals. The serum CRP and RF are markers of 
systemic inflammation and antibody production against the injected adjuvant. 
High levels of serum CRP (8.24 mg/dL) and serum RF (76  IU/mL) were 
observed in the CFA control group rats. The Kanthaga Parpam and Diclofenac 
sodium treatments reduced the increase in the levels of both CRP and RF in the 
serum. The effects of Kanthaga Parpam were dose-dependent, and the 
50 mg/kg dose of Kanthaga Parpam and 45 mg/kg dose of Diclofenac 
sodium had almost equipotent effects in decreasing the serum RF levels.  
 Kanthaga Parpam treatment favorably affected the pain scores, 
indicating a significant decrease in the pain associated with the adjuvant-
induced arthritis. All the estimated pain scores, including the flexion pain test 
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score, mobility score and stance score were significantly altered in Diclofenac 
sodium treated and Kanthaga Parpam (50 mg/kg) -treated rats. The reduction 
in the mobility score was greater in the Kanthaga Parpam (50 mg/kg) -treated 
group as compared with the standard drug treated group. It is clearly observed 
in the lab investigation and histopathology of joint that the soft tissue swelling 
around the joints, periarticular bone resorption, periarticular bony erosions and 
joint space narrowing in the rats treated with Kanthaga Parpam have been 
protected from the CFA-induced arthritis-related joint changes. 
DISCUSSION 
 Rheumatoid arthritis, which is associated with systemic inflammatory 
disorders, is a chronic inflammatory disease involving multiple joints. It is an 
autoimmune disorder of unknown etiology that is characterized by progressive 
joint destruction, deformity, disability and premature death in most patients. 
Recent studies have revealed the key roles of pro-inflammatory cytokines, such 
as tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b), IL-6 and IL-8 in the 
pathogenesis of Rheumatoid arthritis. Inflammation, which is a highly 
coordinated process, is characterized by leukocyte migration into injured 
tissues.  
 The transition of leukocytic infiltrate from neutrophils to monocytes is a 
critical step in the successful resolution of inflammation that is regulated by IL-
6 through orchestrating the chemokine-directed attraction and apoptotic 
clearance of leukocytes. IL-8, CXCL1 and CXCL2 are the main chemotactic 
mediators involved in neutrophil recruitment. CCL2, on the other hand, is a 
potent chemoattractant for monocytes. IL-6 and IL-8 are considered early 
markers of the inflammatory cascade. The correlation between the gene 
expression of IL-6 and other measured chemokines.  
 The gene expression of IL-8, however, was not correlated to any of 
them, suggesting that IL-6 but not IL-8 induces the expression of CCL2, 
CXCL1 and CXCL2. It is known that various cell types respond to IL-6, which 
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magnifies the importance of its role in inflammatory conditions. CFA is a 
mixture of non-metabolizable oil (mineral oil) and mycobacteria. CFA contains 
heat-killed mycobacteria (Mycobacterium tuberculosis) and is more potent to 
induce hyperalgesic inflammatory reaction.  
 CFA acts by prolonging the lifetime of injected auto antigen, by 
stimulating its effective delivery to the immune system and providing a 
complex set to the innate compartment of the immune system resulting in 
altered leukocyte proliferation and differentiation. It causes chronic 
inflammatory response that may be severe and painful for the animal 
depending on the site as well as the quantity and quality of adjuvant induced. 
CFA-induced arthritis is the most widely used chronic test model in which the 
clinical and pathological changes are comparable with those seen in human 
rheumatoid arthritis.  
 Chronic inflammation in the CFA model is manifested as a progressive 
increase in the volume of the injected paw. It is noteworthy that the inhibitory 
effect of Kanthaga Parpam (50 mg  kg −1 day −1) on the volume of the 
injected paw was comparable with that of Diclofenac sodium 
(45 mg  kg −1 day −1).CFA-induced polyarthritis is associated with an 
immune-mediated inflammatory reaction and the rat is unique in developing 
polyarthritis after CFA treatment. The initial reaction of edema and soft-tissue 
thickening at the depot site in this model is caused by the irritant effect of the 
adjuvant, whereas the late-phase arthritis and flare in the injected foot are 
presumed to be immunologic events. The appearance of secondary lesions, that 
is, non-injected paw swelling is a manifestation of cell-mediated immunity. 
The suppression of such secondary lesions by a drug shows its 
immunosuppressive activity.  
 Kanthaga Parpam effectively reduced the secondary lesions in arthritic 
rats. Moreover, this effect of Kanthaga Parpam was more potent than that of 
diclofenac. This reveals potent suppression by Kanthaga Parpam of cell-
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mediated immunity in arthritic rats. Similarly, it reduced the arthritic score and 
secondary paw swelling. A selective reduction in the arthritis score 
distinguishes the immunosuppressive effects of a drug from its anti-
inflammatory effects. The reduction of the arthritis score by Kanthaga Parpam 
as observed in our study indicates a possible immune suppressant effect. CFA-
induced arthritis in rats is associated with an increase in the plasma levels of 
RF and CRP.  
 The treatment with Kanthaga Parpam significantly reduced the levels of 
these biomarkers of inflammation and autoimmune stimulation in the treated 
rats. This study includes examination of the paws, haematological parameters, 
body weight changes, organ weight changes and paw withdrawal latency. The 
visual  observations of the rats show that the treatment with Kanthaga Parpam 
and Diclofenac inhibited the arthritis-associated joint changes. In the Kanthaga 
Parpam and Diclofenac treated groups there was restoration of the body 
weights of the rats. A report suggests that the decrease in the body weight 
during inflammation is due to deficient absorption of nutrients through the 
intestine and that treatment with anti-inflammatory drugs normalizes the 
process of absorption.  
 The evident restoration of the body weight of rats in the Kanthaga 
Parpam and Diclofenac-treated groups may involve improvement of intestinal 
absorption of the nutrients and a reduction in the distress caused by the severity 
of the arthritis. It has been reported that a moderate rise in the WBC count 
occurs in arthritic conditions due to an IL-1B-mediated rise in the respective 
colony-stimulating factors. The present study reveals that Kanthaga Parpam 
25mg/kg and Diclofenac treatments tend to normalize the WBC count. In 
addition to this, other characteristic haematological alterations such as the 
decreased Hb count and increased erythrocyte sedimentation rate were also 
altered by the Kanthaga Parpam and Diclofenac treatments. It is proposed that 
the reduction in the Hb count during arthritis results from reduced 
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erythropoietin levels, a decreased response of the bone marrow erythropoietin 
and premature destruction of red blood cells.  
 Similarly, an increase in the ESR is attributed to the accelerated 
formation of endogenous proteins such as fibrinogen and α/β globulin, and 
such a rise in the ESR indicates an active but obscure disease process. Thus, the 
reduction in the ESR and increase in the Hb count brought about by Kanthaga 
Parpam treatment further support its anti-arthritic effect.  
CONCLUSION 
 In the present study, based on the above results and reasons it can be 
concluded that the Kanthaga Parpam treatment at a dose of 25 and 50 mg/kg 
body wt. significantly inhibit the progression of the rheumatoid arthritis in 
animal models. So, this drug can be used clinically with minimum dose 
employed in this study. 
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Table 2: Effect of Kandhaga Parpam on CFA-induced chronic arthritis in albino rats 
Treatment Dose Mean paw edema (ml)± S.E.M 
Day 1 Day 7 Day 14 Day 21 
Control 3ml/kg p.o. 0.20± 0.04 0.28±0.05 0.35±0.06 0.25±0.06 
Kandhaga Parpam 25 mg kg−1 day−1, p.o. 0.16±0.04 0.26±0.04 0.19±0.03 0.16±0.03 
Kandhaga Parpam 50 mg kg−1 day−1, p.o.), 0.11±0.02 0.18±0.03 0.11±0.03 0.09±0.02 
Diclofenac sodium (45 mg kg−1 day−1, p.o.). 0.08±0.02 0.15±0.03 0.12±0.04 0.10±0.03 
Results are expressed as mean ± S.E.M. (n=6). The significance of results was considered statistically significant at *P < 0.05 
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Table 4: Effect of Kandhaga Parpam on Hematological and Biochemical Parameters in CFA-induced arthritic rats 
Parameters Normal control Arthritic 
Control 
KP (25mg/kg/ day) KP (50mg/kg/ day) Diclofenac 
(45mg/kg/ day) 
Hb (g/dl) 18.66 ±1.42 19.00 ± 1.26 17.05 ± 0.92 14.98 ± 0.86 19.04 ± 1.05 
PCV (%) 61.58 ± 1.86 59.99 ±1.72 60.77 ±1.28 61.18 ±1.60 61.23 ±1.44 
RBC ( x106/ml) 6.24 ± 0.12 6.24± 0.10 5.36 ±0.07** 5.20 ±0.09** 7.64 ± 0.12** 
WBC(103/mm3) 9224±206 9310±212 9410±217 9448±256 9324±244 
ESR(mm/hr) 2±00** 8.15±0.25 6.52±1.04 4.38±1.42* 3.24±1.00** 
Creatinine (mg/dL) 0.44±0.03* 0.68±0.08 0.53±0.07 0.51±0.06 0.49±0.04 
Total Protein (g/dL) 5.50±0.18 5.45±0.20 5.54±0.19 6.22±0.23* 5.72±0.21 
SGOT (IU/L) 129.11±4.25 131.41±4.72 130.20±5.61 172.11±6.32** 180.02±5.98** 
SGPT(IU/L) 44.95±1.72 45.79±2.00 47.02±1.88 46.33±1.51 46.12±1.42 
ALP (IU/L) 51.22±4.45 49.64±3.88 50.26±3.95 51.08±4.20 52.00±4.12 
CRP (mg/dL) 3.14±0.18** 8.24±0.73 6.20±0.36* 5.03±0.31** 4.64±0.52** 
RF (IU/mL) 25.05±0.79** 76.58±2.62 44.16±0.88** 38.51±1.04** 33.25±1.44** 
Values are mean ± SEM of 6 animals. One-way ANOVA followed by Dunnet test. *p<0.05, ** p<0.01 Vs arthritic control 
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Table 3: Effect of Kandhaga Parpam on body weight changes in CFA-induced arthritic albino rats 
Treatment Dose Changes in Body Weight (g) 
Day 1 Day 7 Day 14 Day 21 
Normal control 3ml/kg p.o. 118.46 ± 3.69 121.02 ± 2.52 124.60 ± 4.40 126.44 ± 3.64 
Arthritic Control (2% CMC) 3ml/kg p.o. 120.15 ± 2.54 122.35 ± 2.47 125.43 ± 5.00 120.63 ± 5.29 
Kandhaga Parpam 25 mg kg−1 day−1, p.o. 124.24 ± 3.00 126.62 ± 2.50 117.21 ± 5.58 115.43 ± 3.15 
Kandhaga Parpam 50 mg kg−1 day−1, p.o.), 126.02 ± 3.58 126.10 ± 2.58 110.54 ± 3.41* 103.89 ± 4.30** 
Diclofenac sodium (45 mg kg−1 day−1, p.o.). 123.36 ± 2.96 122.41 ± 3.46 124.23 ± 5.74 130.26 ± 5.95 
Values are mean ± SEM of 6 animals. One-way ANOVA followed by Dunnet test. *p<0.05, ** p<0.01 Vs arthritic control 
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. BIO STATISTICAL ANALYSIS 
Treatment for Kumba vatham 
The most popular statistical tool, namely, Fisher’s Exact Test analysis 
has been employed to analyses the effectiveness with the help of a hypothesis. 
Hypothesis 
There is no reduced of symptoms among the patients for the treatment of 
Kumba vatham. 
 
 
 
Symptoms 
Number of Cases 
Reduced Not Reduced 
Acute pain in the shoulder 
joints 
 
28 
93.3% 
 
2 
6.7% 
Acute pain in the shoulder 
joints , Tenderness,Stiffness, 
Difficult in moving the 
shoulder joints. 
 
4 
66.7% 
 
2 
33.3% 
Acute pain in the shoulder 
joints , Tenderness, Radiating 
pain 
 
2 
50% 
 
2 
50% 
 
Software: spss17 version 
Number of cases: 40 
Test: Fisher’s Exact test 
Confidence Interval: 95% 
 
Result: 
P Value (2 tailed): p<0.05 
Inference:  
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Since the p value is significant (<o.05), The hypothesis is not accepted. 
So there is significant reduced of symptoms among the patients for the 
treatment of Kumba vatham. Hence it is concluded that the treatment was 
effective and significant. 
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CONSENT FORM 
 
          I certify that I have disclosed all the details about the study in the terms 
readily understood by the patient.  
 
 
DATE :                                                                        SIGNATURE  
                                                                                     NAME 
 
 
CONSENT BY THE PATIENT 
 
           I have been informed to my satisfaction by the attending physician for 
the purpose of the clinical trial and the nature of the drug treatment and follow 
up including the lab investigation to be performed to monitor and safeguard my 
body functions. 
           I am aware of my right to opt out of the trial at any time during the 
course of the trial without having to give reasons for doing so. 
           I ,exercising my free power of choice, here by  give my consent to be 
included as a subject in the clinical trial of  KANTHAGA PARPAM  for the 
treatment of  KUMBAVATHAM. 
 
 
 
 DATE:                                                                                       SIGNATURE   
                                                                                                    NAME                    
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§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø ÀÊÅõ 
 
 
           ¾¢Õ. ___________________________¬¸¢Â ¿¡ý 
___________ÅÂÐ,         
(____________________________________________________
_____________________________________________________
____________Åº¢ìÌõ þ¼õ.) ±ý ÍÂ ¿¢¨É×¼ý ±Ø¾¢ì ¦¸¡ÎìÌõ 
´ôÒ¾ø ÀÊÅõ. 
  
          ¿¡ý ÌõÀÅ¡¾õ ±ýÛõ §¿¡Â¡ø À¡¾¢ì¸ôÀðÎ ¦ºý¨É,«ÃÍ 
º¢ò¾ ÁÕòÐÅ ¸øæ¡¢Â¢ø (þ¼õ: «È¢ï÷ «ñ½¡ þó¾¢Â 
ÁÕòÐÅÁ¨É, «ÕõÀ¡ì¸õ, ¦ºý¨É-106.) ¿¼ò¾ôÀÎõ º¢ò¾ 
ÁÕòÐÅ ¬Ã¡öîº¢ ãÄõ º¢¸¢î¨º ¦ÀÈ ±ý ÍÂ ¿¢¨É×¼ý 
ÓØºõÁ¾ò¨¾Ôõ ¦¾¡¢Å¢òÐì¦¸¡û¸¢§Èý. 
 
          þó¾ ¬Ã¡öîº¢Â¢ý §¿¡ì¸õ, ÁÕòÐÅõ ¦ºöÔõ Ó¨È, 
¦¾¡¼÷¸ñ¸¡½¢ôÒ ÁüÚõ ±ý ¯¼ø ¿Äõ ÌÈ¢ò¾ ÁÕòÐÅ 
À¡¢§º¡¾¨É¸¨Çô ÀüÈ¢Â Å¢¡¢Å¡É Å¢Çì¸õ ±ÉìÌ ÁÕòÐÅõ ¦ºöÔõ 
ÁÕòÐÅ÷ ãÄõ ¦¾Ç¢×ÀÎò¾ôÀðÎûÇÐ. þó¾ ¬Ã¡öîº¢Â¢ø 
ÀíÌ¦¸¡ûÙõ ±ý ºõÁ¾ò¾¢üÌ Â¡Õ¨¼Â ¿¢÷Àó¾Óõ 
¸¡Ã½Á¢ø¨Ä±ýÀ¨¾ ¦¾¡¢Å¢òÐì¦¸¡û¸¢§Èý. 
 
 
þôÀÊìÌ, 
 
 
 
 
 
¦ÀÂ÷     : 
Ó¸Å¡¢  : 
 
¿¡û      : 
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CASE SHEET  
POST GRADUATE DEPARTMENT - BRANCH-I 
 (POTHU) MARUTHUVAM  
GOVT. SIDDHA MEDICAL COLLEGE & ANNA HOSPITAL, CHENNAI-106. 
CASE SHEET PROFORMA FOR “KUMBAVATHAM” 
WARD NO. : NATIONALITY : 
I.P. NO : RELIGION : 
BED NO : OCCUPATION : 
NAME : INCOME : 
AGE : D.O.A : 
SEX : D.OD                            : 
PERMANENT ADDRESS :  
  DIAGNOSIS : 
 
TEMPORARY ADDRESS:  
Govt. Siddha Medical College & 
Anna Hospital, Chennai – 106.                            MEDICAL OFFICER : 
 
 
 
COMPLAINTS AND DURATION : 
 
 
 
 
 
HISTORY OF PRESENT ILLNESS: 
 
 
 
 
HISTORY OF PAST ILLNESS : 
 
 
 
 
 
PERSONAL HISTORY & HABITS : 
1. Diet          : Veg.   Non veg.    
2. Marital status    : single               married 
3. Emotional stress  : Yes          No 
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4. Addiction    : Yes   No 
• If yes specify :_____________________________________________ 
5. Bowel habit    : Regular  Constipation 
6. Sleep     : Good                     Disturbed                
Insomnia 
7. Presence of anxiety   : Yes   No 
 
 
FAMILY HISTORY: 
• Cardiovascular disease  Yes 
 No 
• Tuberculosis   Yes  No 
• Others   Yes  No 
 
If yes specify :                                                                                 . 
 
 
GENERAL EXAMINATION: 
1. Physical build :      lean                    normal                   obese  
2. Height (cm) : 
3. Weight(kg)  : : 
4. Pulse rate  : 
5. Heart rate : 
6. Respiratory rate : 
7. Blood pressure  : 
8.  Pallor   : 
9. Cyanosis  : 
10. Jaundice : 
11. Clubbing  : 
12. Pedal oedema : 
13. JVP :  
 
 
 
SYSTEMIC EXAMINATION: 
• CVS   : Normal
 Abnormal 
o If abnormal , 
details_______________________________________ 
159 
 
• CNS  : Normal
 Abnormal 
o If abnormal , 
details_______________________________________ 
• Respiratory system     : Normal
 Abnormal 
o If abnormal , 
details_______________________________________ 
 
• Digestive system : Normal
 Abnormal 
o If abnormal , 
details_______________________________________ 
• Urogenital  system : Normal
 Abnormal 
o If abnormal , 
details_______________________________________ 
SIDDHA ASPECTS 
Yaakai (udal nilai)      Mukkunam  
1. Vatham        1. 
Sathuva gunam 
2. Pitham       2. 
Raasatha gunam  
3. Kapham       3. 
Thamo gunam 
4. Kalappu 
PARUVA KAALAM (SEASONS)   
1. Kaar Kaalam (Aavani-Puratasi) Aug-sept.    
2. Koothir Kaalam (Iypasi-Karthigai) Oct-Nov.  
3. Munpani  Kaalam (Maargazhi-Thai) Dec-Jan 
4. Elavenil Kaalam (Chithirai-Vaikasi) Apr-May  
5. Mudhuvenil  Kaalam (Aani-Aadi) Jun-Jul 
 
NILAM (PLACES)  
                1.Kurinchi (Hills  Areas) 
 2.Mullai (Forest Areas) 
 3.Marudham (Fertile Areas) 
 4.Neithal (Sea Areas) 
 5.Paalai (Desert Areas) 
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IYAMPORIGAL/PULANGAL  
  
1. Mei  (Sensation)  : 
2. Vaai (Taste)  : 
3. Kann  (Vision)  : 
4. Mooku(Smell)  : 
5. Sevi (Hearing) : 
 
KANMENTHIRIYAM / KANMAVIDAYAM 
 
 1.Kai [Koduthal] : 
 2.Kaal [Nadathal] : 
 3.Vaai [Pesal] : 
 4.Eruvai [Malam Kazhithal] :  
 5.Karuvai [Aananthithal] : 
MUMMALAM 
1. Malam 
2. Moothiram 
3. Viyaravai 
 
UYIR THATHUKKAL: 
 Vatham: 
1. Pranan :  6.  Naagan: 
2. Abanan :  7.  Koorman: 
3. Viyanan :  8.  Kirukaran: 
4. Udhanan :  9.  Devadathan: 
5. Samanan:  10. Dhananjeyan: 
PITHAM:   KAPHAM: 
1. Anal Pitham:  1.  Avalambagam: 
2. Ranjaga Pitham:   2.  Kledagam: 
3. Saadhaga Pitham:   3.  Podhagam: 
4. Aalosaga Pitham :  4.  Tharpagam: 
1. Prasaga Pitham:  5.  Santhigam: 
UDAL THATHUKKAL: 
1. Saaram : 
2. Senneer :  
3. Oon : 
4. Kozhuppu : 
5. Enbu : 
6. Moolai : 
7. Sukkilam / Suronitham: 
ENVAGAI THERVU: 
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1. Naa -  
2. Niram              - 
3. Mozhi -  
4. Vizhi -  
5. Sparisam         - 
6. Malam  
a. Niram 
b. Nurai 
c. Erugal   
d. Elagal 
7. Moothiram 
a.  Neerkuri  
1.  Niram 
2. Edai 
3. Manam 
4. Nurai 
5.  Enjal 
b. Neikuri 
8. Naadi 
  
Neikuri examination: 
             Before treatment:  After treatment: 
  
 
 
 
 
 
          SIGNS AND SYMPTOMS                              
                                                                        PRESENT                           
ABSENT 
• Pain in shoulder joints 
• Tenderness 
• Stiffness 
• Difficulty to move the joint 
• Radiating pain 
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Assessment Before 
Treatment 
After Treatment 
I II III IV 
Pain in shoulder 
joints 
     
Tenderness      
Stiffness      
Difficulty to move 
the joint 
     
Radiating pain      
 
LABORTORY INVESTIGATIONS: 
Blood: 
S.No Parameters Before 
 treatment 
After 
treatment 
 TC   
 DC   
 Hb gms%   
 ESR  30 mints 
          60 mints 
  
 Blood Sugar  (F) 
                        (P) 
  
 S.Cholesterol   
 B.Urea   
 B.Creatinine   
          
   Urine:                         
1. Albumin   
2. Sugar   
3. Deposits   
 
 
OTHER INVESTIGATION: 
SHOULDER JOINT AP & LATERAL VIEW 
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TRAIL DRUG       :    KANTHAGAPARPAM 
Dose                        :   200 mg b.i.d after food 
Anubanam             :    Honey  
Duration of treatment:  20 days 
Pathiam (Do’s and Don’ts) 
 
 
 
Prognosis at the end of the treatment 
 
 
 
 
 
 
 
 
Medical Officer Signature: PROF./ H.O.D         
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